Encephalitis Lethargica: The Biggest Medical Mystery of the 20th Century May Not Be History

Reexamining Encephalitis Lethargica in the Era of ME/CFS and Long COVID

This paper is part of the CYNAERA Long COVID and ME/CFS Libraries , a growing collection of research advancing how infection-associated chronic conditions are understood, measured, and addressed.

By Cynthia Adinig

1. Introduction

More than one hundred years ago, the world witnessed one of the most perplexing neurological epidemics in modern medical history. Encephalitis lethargica (EL), often called “sleeping sickness,” affected hundreds of thousands of people across multiple continents during the early twentieth century. Patients developed an extraordinary spectrum of symptoms that included overwhelming sleepiness, abnormal eye movements, tremors, rigidity, paralysis, psychiatric disturbances, speech impairment, and prolonged neurological disability. While some individuals recovered, many remained permanently disabled or died, leaving physicians with a syndrome that resisted explanation despite decades of investigation (Bassoe, 1919; Hoffman and Vilensky, 2017). For more than a century, researchers have searched for the cause of encephalitis lethargica. Influenza, autoimmune disease, viral encephalitis, toxic exposures, post-infectious inflammation, and numerous other hypotheses have been proposed, yet none has fully explained the epidemic’s remarkable clinical diversity or why similar cases continue to appear sporadically today (Dale et al., 2004; McCall et al., 2008; Hoffman and Vilensky, 2017; Brainin, Teuschl and Gelpi, 2024). The persistence of this uncertainty has established encephalitis lethargica as one of neurology’s enduring unsolved diseases.

A Different Question

Most historical investigations have focused on identifying the pathogen responsible for encephalitis lethargica. This paper approaches the problem from a different perspective. Rather than asking what caused encephalitis lethargica, it asks whether modern medicine already recognizes much of the syndrome under different diagnostic names. During the century since the epidemic, medicine has undergone a profound transformation in its understanding of chronic illness following infection. Entire fields that did not exist when physicians first described encephalitis lethargica now shape modern clinical practice, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long COVID, dysautonomia, postural orthostatic tachycardia syndrome (POTS), central disorders of hypersomnolence, neuroimmunology, viral persistence, and the broader framework of infection-associated chronic conditions (IACCs) (Institute of Medicine, 2015; Komaroff and Lipkin, 2023; National Academies of Sciences, Engineering, and Medicine, 2024). These advances provide an opportunity to reinterpret historical observations through scientific concepts that were unavailable to physicians practicing in the early twentieth century.

Looking at Historical Disease Through a Modern Lens

Viewed through contemporary neuroimmune medicine, historical descriptions of encephalitis lethargica appear strikingly familiar. Extreme hypersomnolence, profound exhaustion, movement abnormalities, cognitive dysfunction, executive impairment, autonomic instability, fluctuating neurological symptoms, and prolonged disability are now recognized across severe ME/CFS and neurological Long COVID. At the same time, many concepts that define these illnesses today, including post-exertional malaise (PEM), orthostatic intolerance (OI), cerebral hypoperfusion, mast cell activation syndrome (MCAS), and complex autonomic dysfunction, were unknown during the original epidemic. Physicians observing patients in 1917 could describe what they saw but lacked the conceptual framework needed to recognize many of the physiological processes now considered central to infection-associated chronic disease.

This historical limitation creates an important opportunity. The question is no longer whether early physicians accurately documented their patients, but whether modern science provides new ways to interpret those observations. Diseases are frequently redefined as diagnostic frameworks evolve, and historical case descriptions often acquire new meaning when viewed through advances in pathology, immunology, neurobiology, and systems medicine. Encephalitis lethargica may represent another example of this process.

Study Hypothesis

This paper proposes that encephalitis lethargica may represent one of the earliest well-documented descriptions of a severe infection-associated neuroimmune phenotype rather than a completely distinct disease that disappeared from human populations. Specifically, it examines whether the syndrome occupies part of the same biological continuum now represented by severe ME/CFS, neurological Long COVID, and related infection-associated chronic conditions. This is not an argument that every historical case of encephalitis lethargica would satisfy modern diagnostic criteria for these illnesses, nor that the diagnoses should be considered interchangeable. Instead, it asks whether advances in neuroimmunology, autonomic medicine, sleep science, and infection-associated chronic disease provide a more coherent framework for interpreting one of medicine’s oldest neurological mysteries.

If this hypothesis is supported, the implications extend well beyond medical history. It would suggest that changes in scientific understanding and diagnostic terminology have obscured biological continuity across generations of patients rather than reflecting the disappearance of a unique disease. More broadly, it would argue that encephalitis lethargica should be reconsidered not simply as a historical epidemic, but as part of a continuing lineage of infection-associated neurological disease that remains clinically relevant today (Hoffman and Vilensky, 2017; National Academies of Sciences, Engineering, and Medicine, 2024).

2.The Disease That Appeared, Spread, and Seemed to Vanish

Encephalitis lethargica entered modern medical history during the First World War, when physicians in Europe began reporting patients with an unusual combination of fever, overwhelming sleepiness, abnormal eye movements, movement impairment, psychiatric symptoms, and altered behavior. Constantin von Economo published his influential description of the syndrome in Vienna in 1917, although Jean-René Cruchet and colleagues had observed similar cases in northern France, and retrospective accounts suggest that related illnesses may have appeared as early as 1915. The disease subsequently spread across Europe, North America, Russia, and other regions, with recurring outbreaks continuing through much of the 1920s. Although exact case counts remain uncertain because surveillance systems and diagnostic criteria varied, the epidemic affected hundreds of thousands of people and left a substantial population with chronic neurological disability (Bassoe, 1919; von Economo, 1929; Foley, 2009; da Mota Gomes, 2020; Rogers et al., 2024).

The timing of the epidemic immediately raised questions because encephalitis lethargica emerged during the same period as the 1918 influenza pandemic. Influenza was therefore proposed as the leading cause, but the epidemiological relationship has never been straightforward. Some probable EL cases preceded the major influenza waves, many patients had no documented influenza illness, and encephalitis lethargica continued to appear after the pandemic had largely subsided. These inconsistencies complicated efforts to establish a direct causal relationship (Foley, 2009; McCall et al., 2008; Mortimer, 2009; Brainin, Teuschl and Gelpi, 2024).

More than a century later, no single pathogen has been consistently identified across historical cases. Influenza virus has generally not been detected in archived EL brain tissue, and subsequent investigations have likewise failed to identify a universal infectious agent. While these findings do not exclude an infectious trigger, they suggest that encephalitis lethargica cannot be explained as a conventional viral encephalitis caused by one organism alone (McCall et al., 2008; Hoffman and Vilensky, 2017; Rogers et al., 2024). Historical accounts also suggest that EL-like syndromes may have predated the recognized epidemic. Physicians described episodes of profound somnolence and neurological dysfunction during earlier respiratory outbreaks, including the influenza pandemic of 1889 through 1892. Although these reports cannot be retrospectively confirmed as encephalitis lethargica, they indicate that similar clinical syndromes may have existed before the twentieth-century epidemic received formal recognition (Bassoe, 1919; Foley, 2009; Di Vito et al., 2023).

A Syndrome Without a Confirmed Cause

Encephalitis lethargica remained a clinical diagnosis throughout the epidemic. Physicians had no laboratory biomarker, imaging study, molecular assay, or pathological test capable of confirming the diagnosis in living patients. Instead, diagnosis depended upon recognizing characteristic combinations of neurological, sleep-related, psychiatric, and movement abnormalities while excluding other causes of encephalitis or neurological disease (Mortimer, 2009; Hoffman and Vilensky, 2017; Rogers et al., 2024).

The syndrome itself proved remarkably heterogeneous. Von Economo described somnolent-ophthalmoplegic, hyperkinetic, and amyostatic-akinetic forms, but patients frequently demonstrated overlapping manifestations that included insomnia, reversal of the sleep-wake cycle, tremor, rigidity, behavioral disturbance, psychiatric symptoms, dysphagia, speech impairment, respiratory abnormalities, autonomic dysfunction, and progressive movement disorders (von Economo, 1929; Foley, 2009; Brainin, Teuschl and Gelpi, 2024). This diversity complicated efforts to determine whether physicians were observing one disease, several closely related syndromes, or multiple biological processes converging on a similar neurological phenotype. The remarkable clinical variability became one of the defining characteristics of encephalitis lethargica. Rather than weakening the diagnosis, this heterogeneity foreshadowed a challenge that continues to confront modern medicine, namely that complex neuroimmune disorders often produce widely different clinical presentations while sharing common underlying biological processes.

The Clinical Course Extended Beyond Acute Illness

Encephalitis lethargica was not simply an acute encephalitic illness followed by recovery or death. Many patients experienced prolonged neurological disability, delayed deterioration, recurrent symptoms, or progressive movement disorders that developed months or years after the initial infection. Postencephalitic parkinsonism, oculogyric crises, cognitive impairment, behavioral changes, and persistent sleep disturbances frequently became the dominant clinical features long after the acute illness had resolved (von Economo, 1929; Sacks, 1973; Mortimer, 2009).

Clinical Course of Encephalitis Lethargica

Stage	Common clinical features	Possible outcomes
Initial illness	Fever, respiratory symptoms, or mild systemic infection	Recovery, neurological progression, or unrecognized infection
Acute neurological phase	Hypersomnolence, ophthalmoplegia, abnormal movements, delirium, autonomic dysfunction	Recovery, persistent disability, or death
Chronic phase	Parkinsonism, sleep disorders, cognitive impairment, behavioral changes, relapsing neurological dysfunction	Long-term disability, recurrent illness, or gradual stabilization

This longitudinal pattern distinguished encephalitis lethargica from many acute neurological infections. For a substantial proportion of patients, the most disabling manifestations appeared after the acute illness or evolved over many years. The syndrome therefore included acute, delayed, chronic, relapsing, and progressive courses rather than a single uniform trajectory.

The Pathology Confirmed Organic Neurological Disease

Autopsy studies consistently demonstrated that encephalitis lethargica was an organic neurological disorder. Pathological findings frequently involved the midbrain, brainstem, basal ganglia, substantia nigra, and surrounding vascular structures. Bassoe described edema, vascular congestion, perivascular inflammatory infiltrates, and small hemorrhages while noting that widespread neuronal destruction was often less extensive than expected given the severity of the clinical illness (Bassoe, 1919; von Economo, 1929; Mortimer, 2009).

The variability of pathological findings proved almost as striking as the variability of the clinical syndrome. Some patients exhibited relatively limited inflammatory changes despite profound neurological impairment, whereas others demonstrated more extensive involvement of brainstem and basal ganglia structures. Modern investigations have likewise failed to identify a single pathological mechanism capable of explaining every historical case. Autoimmune processes, post-infectious inflammation, persistent infection, vascular injury, and immune-mediated basal ganglia dysfunction have all been proposed, but no unifying explanation has emerged (Dale et al., 2004; Hoffman and Vilensky, 2017; Rogers et al., 2024). The absence of a universal pathological mechanism should not be interpreted as evidence that encephalitis lethargica lacked a biological basis. Rather, it suggests that the syndrome may have been biologically heterogeneous, with multiple pathways capable of producing a recognizable clinical phenotype.

Did the Disease Disappear, or Did the Diagnosis?

Reports of acute encephalitis lethargica declined sharply after the late 1920s, yet thousands of survivors continued living with chronic neurological disability for decades. Many developed postencephalitic parkinsonism or other disabling neurological sequelae, and some later became widely known through Oliver Sacks’ descriptions of patients who temporarily regained function following treatment with levodopa (Sacks, 1973; Foley, 2009).

Although the epidemic ended, the disappearance of the diagnosis has remained more certain than the disappearance of the syndrome itself. Sporadic EL-like cases have continued to be reported, and modern reviews acknowledge that similar clinical presentations still occur despite the absence of another epidemic of comparable scale (Foley, 2009; Rogers et al., 2024). At the same time, twentieth-century neurology underwent rapid specialization, allowing patients with predominant movement disorders, sleep abnormalities, psychiatric manifestations, autonomic dysfunction, or chronic post-infectious disability to be classified within increasingly distinct diagnostic categories.

Whether encephalitis lethargica truly disappeared or gradually became distributed across newer neurological diagnoses remains unresolved. That question forms the central premise of this review. Rather than assuming that the syndrome vanished completely, the following sections examine whether advances in modern neuroimmunology and infection-associated chronic disease provide a new framework for interpreting one of medicine’s oldest unresolved neurological disorders.

3. The Symptoms Medicine Did Not Yet Know How to See

The physicians who cared for patients with encephalitis lethargica documented one of the most devastating neurological syndromes of the twentieth century with remarkable clinical precision. They described profound sleep disturbances, abnormal eye movements, tremors, rigidity, paralysis, speech impairment, behavioral changes, and prolonged neurological disability, creating a historical record that remains indispensable today (von Economo, 1929; Foley, 2009; da Mota Gomes, 2020; Rogers et al., 2024). Yet these clinicians practiced decades before the emergence of neuroimmunology, autonomic medicine, modern sleep science, and infection-associated chronic disease research. They accurately documented what they observed but lacked the scientific framework necessary to interpret many of the physiological processes underlying those observations.

This distinction is fundamental when interpreting historical disease. Clinical records reflect not only what patients experienced but also the questions physicians knew to ask and the mechanisms available to explain those experiences. Concepts now central to infection-associated chronic illness, including post-exertional malaise (PEM), orthostatic intolerance (OI), cerebral hypoperfusion, mast cell activation syndrome (MCAS), autonomic dysfunction, and central hypersomnolence, had not yet entered clinical medicine. Their absence from the historical literature therefore cannot be interpreted as evidence that these physiological abnormalities were absent.

As medical knowledge advances, previously broad symptom descriptions are often divided into distinct biological processes. Terms such as weakness, lethargy, or fatigue may later prove to represent impaired cerebral perfusion, autonomic instability, exertional intolerance, inflammatory signaling, or abnormalities of sleep regulation. The historical record of encephalitis lethargica should therefore be viewed not as an incomplete clinical effort, but as a detailed observational record constrained by the scientific vocabulary of its era.

Post-Exertional Malaise Was Invisible

Post-exertional malaise is now recognized as the defining feature of ME/CFS and is increasingly reported in neurological Long COVID. Unlike ordinary fatigue, PEM describes pathological worsening following physical, cognitive, emotional, orthostatic, or sensory exertion. Symptoms often worsen after a delay and may require days or weeks for recovery, while patients with severe disease may deteriorate after speaking, eating, reading, sitting upright, or performing basic self-care (Institute of Medicine, 2015; National Academies of Sciences, Engineering, and Medicine, 2024).

No comparable framework existed during the encephalitis lethargica epidemic. Physicians documented whether patients could move, speak, stand, or swallow during an examination but did not routinely determine whether these activities produced delayed neurological deterioration. Historical records therefore describe observed performance rather than sustainable physiological capacity, an important distinction because patients with severe neuroimmune disease may briefly accomplish an activity that cannot safely be repeated.

Descriptions of paradoxical kinesia illustrate this limitation. Some patients with profound akinesia could suddenly move in response to strong emotional or environmental stimuli before returning to their previous neurological state. Without longitudinal assessment, clinicians could not determine whether these brief episodes were followed by prolonged neurological worsening, the phenomenon now recognized as post-exertional malaise (von Economo, 1929; Sacks, 1973; Hoffman and Vilensky, 2017). The clinically meaningful question was not whether movement occurred once, but whether it could be sustained without worsening the underlying disease.

Orthostatic Intolerance Was Hidden Within “Lethargy”

Modern autonomic medicine has demonstrated that remaining upright imposes significant physiological demands on susceptible patients. Orthostatic intolerance can produce dizziness, weakness, cognitive slowing, visual disturbance, tremulousness, altered speech, nausea, headache, presyncope, reduced cerebral blood flow, and impaired functional capacity. Many patients experience marked neurological deterioration while upright despite relatively normal routine blood pressure or heart rate measurements (Dani et al., 2021; van Campen, Rowe and Visser, 2022).

These mechanisms were unknown during the encephalitis lethargica epidemic. Patients who became progressively weaker, less responsive, or increasingly somnolent after sitting or standing were generally described as lethargic or apathetic because physicians lacked methods to evaluate autonomic function or cerebral perfusion. Consequently, posture-dependent neurological impairment was incorporated into broader descriptions of lethargy rather than recognized as a distinct physiological process.

Modern studies further demonstrate that some patients preserve substantially greater cognitive and physical function while lying flat because recumbency improves cerebral perfusion and reduces autonomic demand. Prolonged bed rest may therefore represent physiological adaptation rather than behavioral withdrawal. This possibility was unavailable to early twentieth-century clinicians but provides an important modern framework for interpreting historical observations.

Feeding Dysfunction Extended Beyond Swallowing

Successful feeding depends upon coordinated neurological, autonomic, gastrointestinal, vascular, and immune function. Severe ME/CFS and Long COVID can disrupt this process through dysphagia, gastrointestinal dysmotility, postprandial hypotension, autonomic dysfunction, mast cell activation, hypersomnolence, and food-triggered neurological deterioration (Dani et al., 2021; Kemp et al., 2019).

Historical reports of encephalitis lethargica include patients who required repeated awakening to eat or drink, exhibited swallowing abnormalities, or developed dysfunction involving multiple organ systems (Mortimer, 2009; Brainin, Teuschl and Gelpi, 2024). Although these findings were carefully documented, clinicians lacked the physiological framework needed to distinguish among impaired swallowing, autonomic dysfunction, altered consciousness, gastrointestinal dysmotility, or immune-mediated food intolerance. Variable responses to food were particularly vulnerable to misinterpretation. Modern clinicians increasingly recognize that nutritional tolerance can fluctuate with immune activation, autonomic stability, cumulative exertion, medication exposure, infection status, and environmental conditions. Unless neurological function is assessed before and after eating, clinically meaningful deterioration may never become part of the medical record despite representing a reproducible biological response.

Fluctuating Motor Function Encouraged Psychiatric Interpretation

Severe infection-associated chronic illnesses frequently produce dramatic fluctuations in neurological capacity. Patients may temporarily lose speech, movement, swallowing, or the ability to remain upright before partially recovering, only to deteriorate again after exertion, infection, sensory stimulation, or autonomic stress. Similar fluctuations appear repeatedly throughout historical descriptions of encephalitis lethargica. Historically, variability itself often became evidence against organic disease. Patients demonstrating greater function during one examination than another were frequently interpreted as hysterical, functional, or psychologically ill because clinicians lacked physiological models capable of explaining rapidly changing neurological performance. Once psychiatric explanations became established, further investigation often ceased, limiting opportunities to identify underlying biological abnormalities.

This process creates a form of observational bias within the historical literature. Symptoms fitting established neurological categories were documented extensively, whereas fluctuating or poorly understood manifestations were more likely to receive psychiatric interpretation or remain incompletely characterized. Consequently, the absence of detailed physiological documentation should not be mistaken for evidence that the underlying biological processes were absent.

Sensory and Environmental Intolerance Had No Clinical Framework

Modern studies have shown that severe ME/CFS and neurological Long COVID commonly involve marked sensitivity to light, sound, heat, odors, touch, motion, fragrances, and chemical exposures. These triggers can worsen cognition, autonomic function, pain, hypersomnolence, tremor, breathing, and overall neurological stability through interactions among neuroimmune activation, autonomic regulation, inflammatory signaling, and vascular physiology (Renz-Polster and Scheibenbogen, 2022).

During the encephalitis lethargica epidemic, no comparable framework existed. Patients who deteriorated in response to environmental stimuli could easily appear emotionally unstable, unusually sensitive, or behaviorally avoidant because clinicians were not systematically evaluating neurological function before and after specific sensory exposures. Environmental intolerance often determines daily functional capacity despite remaining largely invisible during brief clinical encounters. Historical physicians documented what occurred within the examination room, but many physiological responses likely unfolded after patients returned to the environments in which they actually lived.

Reading the Historical Record Through Modern Medicine

The historical record of encephalitis lethargica is incomplete not because early physicians failed to observe carefully but because every generation of medicine is constrained by its scientific framework. Early clinicians accurately documented hypersomnolence, tremor, rigidity, paralysis, abnormal eye movements, behavioral disturbance, and prolonged disability because these phenomena fit the neurological knowledge of their time. They could not systematically recognize delayed exertional worsening, cerebral hypoperfusion, autonomic dysfunction, sensory-triggered deterioration, mast cell activation, or fluctuating sustainable capacity because these concepts had not yet entered clinical medicine.

Recognizing these limitations changes how historical observations should be interpreted. Rather than viewing the absence of modern diagnostic terminology as evidence that these physiological processes were absent, the encephalitis lethargica literature can instead be understood as a remarkably detailed clinical record awaiting reinterpretation through advances in neuroimmunology, autonomic medicine, sleep science, and infection-associated chronic disease research. Once viewed through this contemporary framework, the similarities between historical encephalitis lethargica and severe neuroimmune illness become substantially more difficult to dismiss as coincidence.

4. When the Symptoms Are Compared, the Distance Begins to Collapse

Encephalitis lethargica has traditionally been portrayed as a neurological disorder unlike anything encountered in modern medicine. By contrast, ME/CFS has often been reduced to a condition defined primarily by fatigue, creating a comparison between the most dramatic descriptions of encephalitis lethargica and the mildest interpretation of ME/CFS. This framing obscures the substantial clinical overlap that becomes apparent when encephalitis lethargica is compared with severe and very severe ME/CFS, particularly cases accompanied by neurological Long COVID.

These patients may develop profound sleep disturbance, cognitive impairment, movement abnormalities, autonomic dysfunction, sensory intolerance, speech impairment, feeding difficulty, and prolonged disability that extend far beyond fatigue alone (Institute of Medicine, 2015; Bateman et al., 2021; National Academies of Sciences, Engineering, and Medicine, 2024). The purpose of this comparison is not to argue that encephalitis lethargica and ME/CFS are identical diseases or that modern diagnostic criteria should be applied retrospectively. Rather, it is to determine whether their observable neurological phenotypes overlap sufficiently to justify reconsidering their relationship. Throughout medical history, diseases once considered unrelated have later been recognized as different manifestations of shared biological processes, while apparently similar syndromes have ultimately proved distinct. Careful comparison of clinical phenotype is therefore an essential first step before questions of mechanism can be addressed.

Functional Disability Shows Remarkable Convergence

Historical accounts of encephalitis lethargica describe patients who became unable to remain awake, initiate movement, communicate effectively, swallow safely, or perform basic activities of daily living. Many required complete assistance with feeding, mobility, hygiene, and personal care, while others remained disabled for years following the acute illness (von Economo, 1929; Bassoe, 1919; Foley, 2009).

Modern descriptions of severe and very severe ME/CFS reveal strikingly similar levels of functional impairment. Patients may become permanently bedbound, unable to tolerate sitting upright, incapable of sustained speech, dependent upon caregivers for nutrition and hygiene, and extraordinarily sensitive to light, sound, touch, or minimal exertion. Severe neurological Long COVID has reproduced many of these same functional outcomes, including profound cognitive dysfunction, dysautonomia, dysphagia, hypersomnolence, and prolonged dependence upon caregivers (Bateman et al., 2021; Davis et al., 2023).

Convergence of Encephalitis Lethargica and IACCs

Clinical domain	Historical encephalitis lethargica	Severe ME/CFS and neurological Long COVID
Sleep	Pathological somnolence, altered consciousness	Hypersomnolence, severe sleep inertia, unrefreshing sleep
Movement	Akinesia, rigidity, tremor	Motor shutdown, tremor, weakness, impaired mobility
Speech	Delayed or absent speech	Reduced verbal output, cognitive-linguistic impairment
Cognition	Behavioral and cognitive disturbance	Brain fog, executive dysfunction, slowed processing
Feeding	Dysphagia, dependence for feeding	Dysphagia, feeding intolerance, nutritional impairment
Autonomic function	Respiratory, circulatory, and temperature abnormalities	POTS, orthostatic intolerance, dysautonomia
Long-term outcome	Chronic neurological disability	Chronic multisystem disability

Phenotypic overlap alone cannot establish disease identity. Nevertheless, it becomes increasingly difficult to argue that these syndromes occupy entirely separate clinical territory when their most severe manifestations produce nearly identical patterns of neurological disability.

Sleep-Wake Dysfunction Extends Beyond Fatigue

Sleep disturbance represented one of the defining characteristics of encephalitis lethargica. Patients fell asleep while standing, eating, speaking, or walking, while others required repeated stimulation simply to remain awake long enough to eat or communicate. Historical observers also described individuals who appeared asleep despite retaining awareness of conversations around them, suggesting disruption of normal sleep-wake regulation rather than ordinary fatigue (von Economo, 1929; Foley, 2009).

Modern sleep medicine has documented central hypersomnia, idiopathic hypersomnia, narcolepsy-like syndromes, prolonged sleep inertia, and severe disturbances of wakefulness following SARS-CoV-2 infection. Similar abnormalities are increasingly recognized among patients with severe ME/CFS, emphasizing that pathological dysregulation of sleep and wakefulness remains a feature of modern infection-associated neurological disease rather than a historical curiosity (Martínez-Salio et al., 2024). The distinction is important because hypersomnolence reflects dysfunction of neurological systems responsible for maintaining wakefulness, not simply the subjective experience of tiredness. This perspective places encephalitis lethargica within a broader spectrum of disorders affecting central arousal networks.

Movement Disorders Reflect Network Dysfunction

Movement abnormalities have traditionally been cited as one of the strongest distinctions between encephalitis lethargica and ME/CFS. Historical patients frequently developed rigidity, tremor, bradykinesia, masked facies, and postencephalitic parkinsonism, features often interpreted as evidence of a fundamentally different disease process.

Modern neurology has demonstrated, however, that parkinsonian syndromes arise from multiple mechanisms beyond idiopathic Parkinson’s disease. Bradykinesia, rigidity, tremor, hypophonia, hypomimia, and gait impairment can arise from neurodegenerative disease, autoimmune disorders, vascular injury, medications, metabolic disturbances, inflammation, infections, and structural brain lesions. SARS-CoV-2 infection has now been associated with multiple reports of reversible post-infectious parkinsonism, suggesting that disruption of basal ganglia circuitry may occur without progressive neurodegeneration (Makhoul et al., 2023; Sulzer et al., 2020). Historical postencephalitic parkinsonism likewise differed from idiopathic Parkinson’s disease in its pathology, progression, and associated neurological features. Rather than separating encephalitis lethargica from modern infection-associated disease, movement disorders may represent one manifestation of widespread dysfunction involving interconnected motor, autonomic, cognitive, and sleep-regulating networks.

Preserved Awareness Despite Minimal Responsiveness

Historical physicians frequently described patients who appeared asleep, immobile, or minimally responsive while remaining aware of their surroundings. Questions could sometimes be answered after prolonged delays, demonstrating preserved consciousness despite markedly reduced outward behavior (Hall, 1924; Foley, 2009). Comparable observations are now reported among individuals with very severe ME/CFS and neurological Long COVID. Patients may be unable to tolerate conversation, initiate movement, or keep their eyes open while remaining fully aware of events around them. Communication may depend upon eye movements, writing, or delayed responses rather than continuous speech.

These observations highlight an important distinction between awareness and responsiveness. Outward immobility should not be interpreted as evidence of absent cognition, particularly in disorders characterized by profound neurological exhaustion and impaired motor initiation.

Speech and Feeding Involve Multiple Neurological Systems

Speech and swallowing disturbances were well-recognized manifestations of encephalitis lethargica, particularly in patients with prominent brainstem involvement. Similar impairments occur in severe ME/CFS and neurological Long COVID, where dysphagia, slowed speech, impaired motor coordination, autonomic dysfunction, and cognitive overload frequently interfere with communication and nutritional intake (Davis et al., 2023; Institute of Medicine, 2015).

These functions require coordinated activity across motor, autonomic, sensory, cognitive, and brainstem networks. Dysfunction affecting several of these systems simultaneously can produce severe impairment without widespread structural destruction of nervous tissue. This systems perspective helps explain why patients across different infection-associated illnesses may experience remarkably similar functional limitations.

A Shared Clinical Phenotype

When examined across major neurological domains, encephalitis lethargica, severe ME/CFS, and neurological Long COVID demonstrate substantial convergence. All three conditions encompass pathological disturbances of sleep and wakefulness, profound functional disability, movement abnormalities, impaired communication, feeding dysfunction, autonomic instability, fluctuating neurological performance, and prolonged disability. Important differences remain, including the prominence of ophthalmoplegia, higher acute mortality, and the pathological findings associated with the historical epidemic. These distinctions deserve careful investigation, but they do not negate the broader pattern of clinical overlap.

The more appropriate scientific question is therefore no longer whether isolated symptoms resemble one another. Instead, it is whether the overall neurological phenotype observed during the encephalitis lethargica epidemic occupies part of the same infection-associated neuroimmune spectrum now represented by severe ME/CFS and neurological Long COVID. Establishing that clinical convergence provides the foundation for examining whether these conditions also share common biological mechanisms.

5. Medicine Could Not Diagnose What It Had Not Yet Discovered

One of the greatest challenges in comparing historical diseases with modern conditions is the assumption that physicians would have documented every clinically important feature if it had been present. This assumption overlooks a fundamental reality of medical history. Clinicians can only recognize patterns that fit within the scientific framework of their time. As medical knowledge evolves, diseases are frequently reinterpreted without the underlying biology changing. The history of medicine is therefore not only a history of disease, but also a history of expanding observation.

The physicians who cared for patients during the encephalitis lethargica epidemic were exceptional clinical observers. Their descriptions of hypersomnolence, movement disorders, psychiatric manifestations, ophthalmoplegia, paralysis, and prolonged neurological disability remain among the most detailed neurological records of the early twentieth century (von Economo, 1929; Bassoe, 1919; Foley, 2009; Hoffman and Vilensky, 2017). Yet they practiced decades before the emergence of neuroimmunology, autonomic medicine, modern sleep science, molecular pathology, functional neuroimaging, and infection-associated chronic disease research. Historical records should therefore be understood as detailed clinical observations interpreted through the scientific vocabulary available at the time rather than complete biological descriptions of disease.

This distinction remains important because retrospective analysis often assumes that missing terminology reflects missing biology. In reality, physicians cannot systematically identify mechanisms that have not yet entered medical knowledge. Modern reinterpretation does not imply that historical clinicians overlooked obvious findings. Rather, it recognizes that advances in science allow previously documented observations to acquire new biological meaning.

Disease Classification Changes with Scientific Progress

Medical history repeatedly demonstrates that disease classification evolves alongside scientific discovery. Multiple sclerosis was once regarded primarily as a white matter disorder before advances in imaging revealed extensive gray matter involvement. Peptic ulcer disease was long attributed to stress and excess acid until the discovery of Helicobacter pylori transformed understanding of its pathogenesis. More recently, autoimmune encephalitis emerged as a distinct category of neurological disease after neuronal autoantibodies were identified, despite almost certainly existing long before they could be measured (Marshall and Warren, 1984; Filippi et al., 2012; Dalmau and Graus, 2018).

Long COVID provides perhaps the clearest contemporary example of this process. During the early years of the pandemic, persistent symptoms were frequently attributed to prolonged recovery, anxiety, or deconditioning. As evidence accumulated, researchers documented immune dysregulation, autonomic dysfunction, endothelial injury, persistent viral antigen, coagulation abnormalities, and multisystem organ involvement across diverse patient populations (Davis et al., 2023; Peluso et al., 2022; National Academies of Sciences, Engineering, and Medicine, 2024). The biology of Long COVID did not fundamentally change during this period. Medicine’s ability to recognize and explain it did.

The same principle deserves consideration when interpreting encephalitis lethargica. Physicians documented the syndrome using the scientific concepts available to them, but the absence of modern terminology should not be interpreted as evidence that contemporary biological mechanisms were absent.

Missing Diagnoses Produce Missing Data

The absence of a diagnostic framework often creates the illusion that an underlying biological process did not exist. Physicians during the encephalitis lethargica epidemic had no recognized concepts of post-exertional malaise, orthostatic intolerance, cerebral hypoperfusion, mast cell activation syndrome, or infection-associated chronic disease. Modern physiological measurements including tilt-table testing, extracranial Doppler assessment of cerebral blood flow, autonomic reflex testing, advanced neuroimaging, and molecular immune profiling would not become available for decades (Institute of Medicine, 2015; van Campen, Rowe and Visser, 2020; Dani et al., 2021).

Consequently, many observations that would now prompt targeted investigation were instead incorporated into broader descriptive categories such as lethargy, weakness, exhaustion, or psychiatric disturbance. The historical literature therefore contains remarkably rich clinical observations but comparatively limited physiological interpretation. This pattern reflects the available scientific tools rather than deficiencies in clinical observation. The same process continues whenever medicine encounters emerging diseases. Before reliable biomarkers or mechanistic models become available, clinicians naturally rely on broad descriptive terminology. As understanding advances, those descriptions are gradually divided into distinct biological processes. Historical encephalitis lethargica should be interpreted within this broader pattern of scientific evolution.

Dynamic Diseases Challenge Static Models

Traditional neurological examinations were designed to determine whether a patient could perform a particular task at a specific point in time. This approach remains highly effective for disorders producing relatively stable deficits, such as stroke or traumatic injury. Infection-associated neuroimmune diseases, however, often fluctuate over hours or days, making brief clinical encounters an incomplete representation of overall function.

Historical physicians generally documented what they observed during individual examinations. Modern clinicians increasingly recognize that patients with severe ME/CFS and neurological Long COVID may demonstrate transient capacity that cannot be sustained without subsequent deterioration. This distinction between momentary performance and long-term functional capacity has become central to understanding chronic neuroimmune illness and highlights an important limitation of historical clinical assessment. Rather than representing shortcomings in early neurological practice, these differences reflect changes in the questions medicine now asks. Contemporary clinicians increasingly evaluate disease longitudinally, recognizing that variability itself may represent an important biological characteristic rather than evidence against organic illness.

Diagnostic Fragmentation Can Conceal Biological Unity

Scientific progress has transformed medicine through increasing specialization. This evolution has produced extraordinary advances in diagnosis and treatment, but it has also encouraged complex multisystem illnesses to be divided among organ-specific disciplines. A patient with neurological, autonomic, gastrointestinal, sleep, and behavioral manifestations may therefore receive multiple accurate diagnoses while no single specialty recognizes the underlying biological connection.

This challenge is particularly relevant for infection-associated chronic conditions. Tremor may be evaluated by neurology, hypersomnolence by sleep medicine, dysautonomia by cardiology, gastrointestinal dysfunction by gastroenterology, mast cell activation by allergy and immunology, and chronic fatigue by rheumatology or primary care. Each diagnosis may accurately describe dysfunction within one physiological system, yet none fully explains the multisystem disease affecting the individual as a whole. Ironically, modern specialization may recreate some of the same uncertainty that surrounded encephalitis lethargica. Rather than disappearing, a complex neuroimmune syndrome becomes distributed across multiple specialties and diagnostic categories. What appears epidemiologically as several unrelated disorders may instead represent different clinical expressions of a shared biological process.

Reinterpreting Historical Disease

Historical medicine should not be judged by what it failed to recognize but appreciated for the extraordinary clinical observations it preserved. Von Economo, Bassoe, Hall, and their contemporaries documented encephalitis lethargica with remarkable detail despite working without the conceptual and technological tools available today. Their work provides a foundation for modern reinterpretation rather than a limitation to overcome (von Economo, 1929; Bassoe, 1919; Hoffman and Vilensky, 2017).

Viewed through advances in neuroimmunology, autonomic medicine, sleep science, and infection-associated chronic disease, the historical record acquires new explanatory possibilities. The central question is therefore no longer whether physicians in 1919 overlooked obvious evidence, but whether modern science now provides biological frameworks capable of explaining observations that remained mysterious for more than a century. Having established both the clinical convergence and the limitations of historical diagnostic frameworks, the next step is to examine whether these conditions also share a common biological architecture.

6. A Shared Biological Architecture

The preceding sections establish substantial clinical convergence among encephalitis lethargica, severe ME/CFS, and neurological Long COVID. Similarities in sleep-wake regulation, movement, cognition, autonomic function, speech, feeding, and long-term disability cannot independently establish shared disease mechanisms, but they justify examining whether these conditions occupy overlapping biological territory. Over the past two decades, advances in neuroimmunology, autonomic medicine, vascular biology, systems neuroscience, and infection-associated chronic disease research have identified recurring mechanisms that extend across pathogens and diagnostic categories. Rather than pointing toward one universal cause, these findings suggest a shared biological architecture through which different infectious triggers may produce overlapping neurological phenotypes.

For much of the twentieth century, investigations of encephalitis lethargica focused on identifying one responsible pathogen. Influenza became the leading hypothesis because the EL epidemic overlapped historically with the 1918 influenza pandemic, yet influenza virus has never been consistently demonstrated in archived EL tissue, and no alternative organism has explained every historical case (McCall et al., 2008; Hoffman and Vilensky, 2017; Brainin, Teuschl and Gelpi, 2024; Rogers et al., 2024). This failure has often been interpreted as evidence against a direct infectious cause, but the limits of the available biological material complicate that conclusion. Many specimens were collected, fixed, stored, and repeatedly handled decades before the development of molecular diagnostics, creating substantial challenges for viral detection more than a century later.

RNA is particularly vulnerable to degradation in formalin-fixed and paraffin-embedded tissue, while prolonged fixation can fragment nucleic acids and chemically modify proteins in ways that reduce the sensitivity of polymerase chain reaction, sequencing, and immunohistochemical methods. Surviving tissue samples may also represent only small regions of the brain, creating sampling limitations if viral material was transient, unevenly distributed, located outside the central nervous system, or cleared before death. A post-infectious process would be even more difficult to establish because the initiating pathogen might no longer be detectable by the time severe neurological dysfunction developed. The absence of consistent viral detection therefore weakens the argument for conventional direct influenza encephalitis but does not exclude an infectious trigger, transient neuroinvasion, persistent infection outside sampled tissue, or an immune-mediated process initiated by infection (McCall et al., 2008; Hoffman and Vilensky, 2017; Rogers et al., 2024).

Modern molecular methods may still provide opportunities to revisit surviving specimens. Next-generation sequencing, targeted RNA sequencing, spatial transcriptomics, proteomics, multiplex immunohistochemistry, and improved methods for recovering degraded nucleic acids from archived tissue could identify pathogen-derived material, immune signatures, or spatial patterns of inflammation that were inaccessible to earlier investigators. These methods cannot reverse every limitation created by specimen age, fixation, tissue scarcity, and incomplete clinical documentation, but they could clarify whether archived EL tissue contains evidence of infection, persistent antigen, autoimmune activation, vascular injury, or host-response pathways shared with contemporary infection-associated neurological disease.

Multiple Pathogens, One Biological Pattern

Modern infection-associated chronic disease demonstrates that similar chronic syndromes can follow a wide variety of infectious triggers. ME/CFS has been associated with Epstein-Barr virus, enteroviruses, influenza, Ross River virus, Q fever, SARS-CoV-1, and gastrointestinal infections, while Long COVID has established SARS-CoV-2 as another potent trigger of prolonged multisystem disease (Hickie et al., 2006; Institute of Medicine, 2015; Komaroff and Lipkin, 2023; National Academies of Sciences, Engineering, and Medicine, 2024). Comparable chronic syndromes have also been described following Ebola virus disease, chikungunya, dengue, Lyme disease, and other infections, reinforcing that persistent post-infectious illness is not unique to one pathogen family (Wilson et al., 2018; Nalbandian et al., 2023). The recurring pattern suggests that infection can initiate chronic disease through shared host-response pathways even when the responsible microorganisms differ substantially.

Pathogen identity may influence clinical expression without fully determining long-term outcome. Different microorganisms can activate overlapping immune pathways, disrupt endothelial function, alter autonomic regulation, reactivate latent infections, impair mitochondrial metabolism, damage neurovascular coupling, or generate persistent antigen exposure. Host factors such as genetics, age, prior infections, immune regulation, hormonal state, environmental exposures, and comorbid conditions may influence which mechanisms persist and which organ systems become most affected. Once established, these interacting processes may reinforce one another and sustain chronic illness long after the acute infection has resolved.

Pathogens Clinical Expression

Biological process	Evidence across infection-associated chronic disease	Potential neurological consequence
Persistent pathogen or antigen	Enteroviral proteins or RNA, SARS-CoV-2 RNA or antigen, tissue reservoirs	Continued immune activation and altered neural signaling
Immune dysregulation	Cytokine abnormalities, altered T-cell and B-cell activity, complement activation	Neuroinflammation, fatigue, cognitive and autonomic dysfunction
Post-infectious autoimmunity	Neuronal autoantibodies, molecular mimicry, immune-mediated encephalitis	Movement, behavioral, sleep, autonomic, or cognitive abnormalities
Neurovascular dysfunction	Endothelial injury, impaired cerebral blood flow, microvascular abnormalities	Cognitive slowing, orthostatic symptoms, sensory and motor impairment
Autonomic dysfunction	POTS, orthostatic intolerance, dysmotility, temperature dysregulation	State-dependent neurological and multisystem deterioration
Brain-network dysfunction	Brainstem changes, altered connectivity, basal ganglia involvement	Disrupted arousal, movement initiation, cognition, and behavioral activation
Metabolic dysfunction	Mitochondrial stress, impaired energy metabolism, oxidative stress	Reduced physiological reserve and exertion-triggered deterioration

These processes should not be understood as mutually exclusive disease categories. Persistent antigen may sustain immune activation, immune activation may impair endothelial and autonomic function, altered cerebral perfusion may worsen cognition and motor control, and metabolic stress may reduce the nervous system’s capacity to compensate. The resulting illness may therefore reflect interacting biological networks rather than one linear pathological pathway.

Persistent Infection and Persistent Immune Activation

Evidence supporting persistent infection or antigen exposure has expanded considerably. Chia and colleagues identified enteroviral capsid protein in gastric biopsy tissue from approximately 82 percent of patients with ME/CFS compared with 20 percent of controls, while enteroviral RNA and non-cytolytic enteroviruses were also detected in subsets of patients (Chia and Chia, 2008).

These findings do not establish enteroviruses as a universal cause of ME/CFS, but they demonstrate that viral material can persist within tissue without producing the extensive cellular destruction expected in acute viral encephalitis. They also illustrate why blood-based testing may fail to identify biological activity concentrated within specific tissue reservoirs.

Long COVID research has produced conceptually similar findings. SARS-CoV-2 RNA, proteins, and antigens have been identified months after acute infection in gastrointestinal tissue, lymphoid tissue, plasma, and other compartments in subsets of patients, suggesting that continuing antigenic stimulation may contribute to sustained immune activation even when active viral replication is limited or difficult to detect (Proal and VanElzakker, 2021; Peluso et al., 2022; Stein et al., 2024). Persistent viral material is unlikely to explain every Long COVID phenotype, but it provides a biologically plausible mechanism for chronic immune signaling in at least part of the population. The heterogeneity of findings is consistent with a disease family involving multiple overlapping pathways rather than one universal mechanism.

The importance of these observations extends beyond the presence of residual pathogen. Persistent infection, retained antigen, defective viral particles, or incomplete immune clearance may each provide chronic stimulation capable of maintaining inflammatory signaling, endothelial injury, autonomic dysfunction, and altered neural activity. In other patients, a transient infection may initiate a self-sustaining immune or autoimmune process that continues after the microorganism has been cleared. The relevant biological question may therefore concern the continuing host-pathogen or host-antigen interaction rather than uncontrolled viral replication alone.

This framework is particularly relevant to encephalitis lethargica because negative testing of archived brain tissue cannot distinguish among several possibilities. The responsible pathogen may have been cleared before death, concentrated outside the sampled tissue, present below the detection threshold of available methods, or never directly invaded the brain. Alternatively, infection may have initiated an immune-mediated neurological process whose downstream effects persisted independently. Each possibility is compatible with severe post-infectious illness without requiring continuing high-level viral replication within the central nervous system.

Immune Dysregulation and Post-Infectious Autoimmunity

Persistent immune dysregulation has emerged as a central theme across infection-associated chronic disease. Long COVID studies have identified abnormalities involving inflammatory cytokines, T-cell activation and exhaustion, B-cell responses, innate immune signaling, complement pathways, monocyte function, and autoantibody production (Davis et al., 2023; Peluso et al., 2022; Klein et al., 2023). ME/CFS research has similarly reported abnormalities involving natural killer cell function, immune signaling, autoantibodies, and altered responses to exertion, although results vary according to cohort, disease duration, and study design (Institute of Medicine, 2015; Komaroff and Lipkin, 2023). This variability may reflect biological subgroups rather than the absence of immune involvement.

Modern investigations of EL-like illness have followed a similar trajectory. Dale and colleagues examined 20 patients with an encephalitis lethargica-like syndrome and identified inflammatory cerebrospinal fluid abnormalities, elevated anti-streptolysin O titers, and antibodies reactive against basal ganglia antigens in most patients (Dale et al., 2004). The authors proposed that the syndrome represented a post-infectious autoimmune disorder affecting deep gray matter structures rather than classical viral encephalitis caused by direct neural invasion. Their findings provided an important biological model for understanding how infection could produce an EL-like neurological syndrome without a consistently detectable neurotropic pathogen.

The interpretation of basal ganglia antibodies nevertheless requires caution. Their presence does not by itself establish that they caused the neurological syndrome, and debate continues regarding whether such antibodies are directly pathogenic, secondary markers of tissue injury, indicators of broader immune activation, or laboratory findings with limited disease specificity. Assay methods, antigen selection, control populations, and reproducibility have all influenced interpretation across studies of post-streptococcal and basal ganglia-associated neurological syndromes. Dale et al. therefore supports the plausibility of immune-mediated EL-like disease, but it does not prove that one autoantibody mechanism explains either the contemporary cases or the historical epidemic.

The broader development of autoimmune neurology strengthens the mechanistic argument without resolving that uncertainty. Anti-NMDA receptor encephalitis can produce psychiatric symptoms, altered consciousness, dyskinesias, autonomic instability, speech disturbance, sleep disruption, and catatonia. LGI1 encephalitis may involve cognitive decline, seizures, movement abnormalities, sleep disruption, and hyponatremia, while CASPR2 and GABA receptor-associated syndromes can produce combinations of encephalopathy, autonomic dysfunction, peripheral nerve hyperexcitability, seizures, and severe neurobehavioral change (Dalmau and Graus, 2018). Many of these conditions were not recognized until neuronal antibodies and modern immunological techniques became available, although the syndromes almost certainly existed long before their molecular classification.

These diseases demonstrate that profound neurological dysfunction can arise through immune-mediated disruption of receptors, ion channels, synapses, and neuronal networks without requiring widespread irreversible destruction of brain tissue. They also demonstrate that different immune targets can produce partially overlapping neurological phenotypes, including sleep disturbance, movement abnormalities, autonomic instability, altered behavior, and impaired consciousness. Encephalitis lethargica may therefore have represented a single immune-mediated syndrome, several immunological subtypes, or a broader clinical category into which multiple post-infectious neurological processes were placed.

Brain Networks Rather Than Individual Lesions

Historical pathology repeatedly implicated the brainstem, basal ganglia, substantia nigra, midbrain, and surrounding vascular structures in encephalitis lethargica. These regions coordinate motor initiation, arousal, autonomic regulation, executive function, emotional processing, ocular movement, reward, and behavioral activation. Modern neuroscience increasingly understands them not as isolated anatomical structures but as components of distributed networks linking the cortex, thalamus, limbic system, hypothalamus, brainstem, and autonomic centers (Alexander, DeLong and Strick, 1986). Disruption within these circuits could therefore produce a broad combination of sleep, motor, cognitive, behavioral, ocular, and autonomic symptoms without requiring the same lesion pattern in every patient.

Neuroimaging studies of ME/CFS and Long COVID increasingly identify altered functional connectivity, brainstem abnormalities, cerebral hypoperfusion, white matter disruption, metabolic changes, and evidence of neuroinflammation rather than consistent large focal lesions (Barnden et al., 2015; Fernández-Castañeda et al., 2024). These findings remain heterogeneous and should not be interpreted as one established imaging signature. They nevertheless support a systems-level model in which distributed neurological dysfunction may produce profound disability despite relatively subtle findings on conventional structural imaging.

Severe neurological impairment does not require extensive neuronal death when the affected networks regulate functions as fundamental as wakefulness, movement initiation, cerebral perfusion, autonomic stability, and cognitive processing. Immune signaling, neurotransmitter disruption, vascular dysfunction, metabolic insufficiency, or altered connectivity may impair several of these functions simultaneously. Because these processes can vary over time, network dysfunction also provides a plausible explanation for fluctuating neurological capacity, temporary improvement, and recurrent deterioration. The patient’s functional state may depend not only upon structural injury but also upon the moment-to-moment stability of interconnected regulatory systems.

Dopaminergic pathways provide one example of this principle. Historical postencephalitic parkinsonism demonstrated that infection-associated injury could produce profound impairment of movement initiation and behavioral activation, while the temporary responses to levodopa later described by Sacks showed that at least some function remained pharmacologically accessible decades after the original illness (Sacks, 1973). These observations do not imply that dopaminergic treatment is appropriate for ME/CFS or Long COVID. They do suggest that severe chronic post-infectious neurological disability can involve modifiable neurotransmitter and network dysfunction rather than irreversible loss of all relevant neurological capacity.

Autonomic and Neurovascular Integration

Autonomic dysfunction provides another major point of biological convergence. ME/CFS and Long COVID are both associated with POTS, orthostatic intolerance, gastrointestinal dysmotility, altered sweating, temperature dysregulation, breathing abnormalities, blood pressure instability, and reduced cerebral blood flow during upright posture (Dani et al., 2021; van Campen, Rowe and Visser, 2020; van Campen, Rowe and Visser, 2022). These abnormalities can impair cognition, movement, speech, vision, alertness, and sensory tolerance, particularly when patients are upright or exposed to additional physiological stress. Autonomic dysfunction therefore connects neurological symptoms with cardiovascular, gastrointestinal, respiratory, and thermoregulatory manifestations.

Historical EL reports documented disturbances of circulation, respiration, digestion, sweating, temperature, bladder function, and other involuntary processes, although these observations predated modern autonomic testing. Viewed collectively, they suggest that autonomic regulation may have been an important component of the syndrome rather than a collection of unrelated complications. Brainstem and hypothalamic involvement could plausibly disrupt arousal, cardiovascular regulation, respiratory control, sleep, and gastrointestinal function within the same patient. The historical terminology did not allow these findings to be organized as a recognizable autonomic phenotype.

Neurovascular mechanisms may further connect these domains. Long COVID research has identified endothelial injury, vascular inflammation, altered coagulation, platelet activation, and microvascular abnormalities, while ME/CFS studies have demonstrated reduced cerebral blood flow and impaired vascular responses during orthostatic stress (Pretorius et al., 2022; van Campen, Rowe and Visser, 2022). Historical EL pathology included vascular congestion, perivascular inflammation, edema, and small hemorrhages in some cases (Bassoe, 1919; Mortimer, 2009). These findings do not establish one shared vascular disease, but they identify the neurovascular interface as a recurring site of dysfunction across historical and modern infection-associated neurological illness.

A Systems Biology Model

Taken together, the available evidence supports a systems biology model of infection-associated chronic disease. Persistent infection or antigen exposure, immune dysregulation, autoimmunity, endothelial injury, autonomic instability, impaired cerebral perfusion, altered neurotransmission, mitochondrial stress, and brain-network dysfunction may interact rather than operate as isolated mechanisms. Different patients may enter this network through different infectious triggers and follow different biological trajectories while arriving at overlapping clinical phenotypes. Heterogeneity is therefore not necessarily evidence against a shared disease family, but may reflect variation in the pathways, tissues, and regulatory systems most affected.

This perspective also offers a possible explanation for the longstanding mystery of encephalitis lethargica. The inability to identify one universally responsible pathogen may not represent failure to solve a single uniform disease. It may instead indicate that the historical syndrome was biologically heterogeneous from the beginning, with different infectious or immune pathways converging on a recognizable neuroimmune phenotype. Variation in pathogen, host response, disease stage, tissue sampling, and dominant neural-network involvement could produce substantial clinical diversity while preserving recurring features involving sleep, movement, cognition, behavior, autonomic regulation, and prolonged disability.

Viewed in this context, encephalitis lethargica, severe ME/CFS, and neurological Long COVID need not be understood as identical diseases. They may instead represent different positions within a broader spectrum of infection-associated neuroimmune disorders linked by recurring biological mechanisms. This framework shifts the central scientific question away from identifying one historical pathogen and toward understanding how infection destabilizes interconnected immune, vascular, autonomic, metabolic, and neurological systems across different diseases, pathogens, and generations.

7. Rethinking Infection-Associated Chronic Disease

The COVID-19 pandemic fundamentally changed medicine’s understanding of what infection can leave behind. Before 2020, prolonged illness following infection was often viewed as uncommon or limited to a small number of poorly understood conditions. Today, Long COVID has demonstrated on a global scale that an acute infection can trigger persistent dysfunction involving the nervous, immune, vascular, endocrine, gastrointestinal, cardiopulmonary, and autonomic systems that may continue for months or years after the initial illness resolves (National Academies of Sciences, Engineering, and Medicine, 2024; Davis et al., 2023; Nalbandian et al., 2023).

Long COVID did not create this phenomenon. Rather, it made visible a pattern that had been described repeatedly across medicine but rarely examined as part of a unified scientific framework. ME/CFS has long been associated with Epstein-Barr virus, enteroviruses, influenza, Ross River virus, Q fever, SARS-CoV-1, and numerous gastrointestinal infections (Hickie et al., 2006; Institute of Medicine, 2015). Similar chronic syndromes have also been documented following Ebola virus disease, Lyme disease, chikungunya, dengue, sepsis, and other serious infections (Wilson et al., 2018; Nalbandian et al., 2023). Although the triggering pathogens differ substantially, many patients develop overlapping patterns of neurological dysfunction, autonomic instability, cognitive impairment, sleep disturbance, fatigue, pain, exercise intolerance, and reduced functional capacity.

These observations suggest that medicine may be witnessing recurring expressions of a broader biological phenomenon rather than a collection of entirely unrelated diseases. Infection appears capable of disrupting common physiological systems through multiple pathways, producing chronic illness that extends beyond the characteristics of the original pathogen. The emergence of Long COVID has therefore expanded the scientific conversation from individual diseases to the broader biology of infection-associated chronic conditions.

From Pathogens to Biological Architecture

Historically, medicine has organized infectious diseases primarily according to the microorganism responsible for the initial illness. Influenza causes influenza, Epstein-Barr virus causes infectious mononucleosis, and SARS-CoV-2 causes COVID-19. This approach has been extraordinarily successful for diagnosing acute infection, guiding treatment, and preventing transmission. Chronic disease, however, does not always follow the same organizational principles.

Increasing evidence suggests that the long-term consequences of infection may depend as much upon the host response as upon the pathogen itself. Persistent immune activation, viral or antigen persistence, endothelial dysfunction, autonomic dysregulation, altered neurotransmission, neurovascular abnormalities, mitochondrial dysfunction, and disrupted brain networks have now been described across multiple infection-associated chronic conditions, despite substantial differences in the infectious agents that initiated them (Komaroff and Lipkin, 2023; Pretorius et al., 2022; Peluso et al., 2022; Fernández-Castañeda et al., 2024). These recurring biological themes suggest that infection-associated illness may be better understood as a spectrum of overlapping neuroimmune disorders than as completely independent diseases defined solely by their initiating pathogen.

This perspective does not replace existing diagnoses, nor does it imply that all post-infectious illnesses share identical mechanisms. Instead, it recognizes that diseases can be classified at more than one level simultaneously. One level describes the triggering infection, while another describes the biological systems disrupted by that infection. Modern oncology, rheumatology, and immunology have increasingly adopted this type of mechanism-based classification as molecular understanding has expanded. Infection-associated chronic disease may be approaching a similar transition.

Encephalitis Lethargica Through a Modern Lens

Within this broader framework, encephalitis lethargica appears less like an isolated historical anomaly and more like an early description of severe post-infectious neurological disease. Throughout this review, historical observations have been compared with contemporary knowledge of severe ME/CFS and neurological Long COVID. Similarities extend beyond individual symptoms and include disturbances of sleep-wake regulation, motor initiation, cognition, autonomic function, speech, swallowing, behavior, and prolonged disability. Modern biological research further demonstrates convergence around immune dysregulation, neurovascular dysfunction, altered brain networks, autonomic instability, and post-infectious neurological injury.

At the same time, important differences remain. Encephalitis lethargica demonstrated higher acute mortality, more frequent ophthalmoplegia, and characteristic movement disorders that distinguish it from most contemporary cases of ME/CFS or Long COVID. These differences should not be minimized, but neither should they prevent broader comparison. Diseases occupying the same biological family frequently display substantial variation in severity, pathology, and clinical expression while sharing fundamental mechanisms. Rheumatoid arthritis, lupus, Sjögren syndrome, and autoimmune thyroid disease illustrate this principle within autoimmunity. Likewise, different viral infections can produce overlapping forms of myocarditis despite involving distinct pathogens. Biological relatedness does not require clinical identity.

The central hypothesis of this review is therefore intentionally conservative. It does not propose that encephalitis lethargica was simply ME/CFS or Long COVID under another name. Instead, it suggests that these conditions may occupy overlapping regions within a broader landscape of infection-associated neuroimmune disease. If so, encephalitis lethargica did not disappear because its biology vanished. It disappeared because medicine developed new diagnostic categories that emphasized different aspects of a continuing biological spectrum.

Why This Matters

The implications extend well beyond historical curiosity. If infection-associated chronic conditions share important biological architecture, then discoveries made in one disease may inform understanding of many others. Biomarkers identified in Long COVID may have relevance for ME/CFS. Research into autonomic dysfunction may improve understanding of post-treatment Lyme disease syndrome. Studies of persistent viral antigen, endothelial dysfunction, or neuroimmune signaling may prove applicable across multiple post-infectious illnesses rather than remaining confined to a single diagnosis. Such cross-disciplinary investigation has the potential to accelerate therapeutic development while reducing unnecessary duplication of research efforts (Komaroff and Lipkin, 2023; National Academies of Sciences, Engineering, and Medicine, 2024).

This perspective also carries practical implications for patients. Many individuals with infection-associated chronic illness spend years moving between specialties, accumulating diagnoses that describe individual organ systems without fully explaining the illness connecting them. Neurology may identify movement abnormalities, cardiology may diagnose POTS, gastroenterology may document dysmotility, sleep medicine may recognize hypersomnolence, and immunology may identify mast cell activation or immune abnormalities. Each diagnosis may be accurate, yet the patient continues to experience one interconnected disease process. Recognizing shared biological architecture encourages multidisciplinary care while preserving the expertise of individual specialties.

For patient communities, this framework also helps explain why seemingly different illnesses often feel remarkably similar. Patients with ME/CFS, Long COVID, post-Ebola syndrome, post-treatment Lyme disease syndrome, and other infection-associated conditions frequently describe comparable experiences of neurological dysfunction, post-infectious disability, diagnostic delay, fragmented medical care, and disbelief despite differing infectious triggers. A shared biological framework provides a scientific basis for understanding these common experiences without suggesting that every disease is identical.

Looking Forward

For more than a century, encephalitis lethargica has been regarded as one of medicine’s great unsolved neurological mysteries. Most attempts to solve that mystery have focused on identifying a single pathogen responsible for a disease that appeared briefly before disappearing. Modern infection-associated chronic disease research suggests another possibility. The enduring mystery may not be the organism itself but the biological response that infection can trigger in susceptible individuals.

Whether future research ultimately confirms, modifies, or refutes the hypothesis presented here, advances in neuroimmunology, autonomic medicine, systems neuroscience, and infection-associated chronic disease have fundamentally changed the scientific context in which encephalitis lethargica should be interpreted. Questions that could not be asked in 1917 can now be investigated using molecular pathology, advanced neuroimaging, immunophenotyping, systems biology, computational modeling, and comparative analyses across multiple post-infectious illnesses. These tools provide an opportunity to revisit one of history’s oldest neurological mysteries with scientific capabilities unimaginable to the physicians who first described it.

Perhaps the most important lesson of encephalitis lethargica is not simply historical. Diseases do not always disappear when the names used to describe them fall out of medical practice. Sometimes they persist while medicine gradually learns to recognize them differently. If infection-associated chronic conditions represent a spectrum of related neuroimmune disorders rather than isolated diseases, then encephalitis lethargica may not stand apart from modern medicine as an unsolved anomaly. Instead, it may represent one of the earliest documented chapters in a continuing story that medicine is only now beginning to understand.

8. Reconstructing the Encephalitis Lethargica Phenotype

If encephalitis lethargica first emerged today, it is unlikely that most patients would receive that diagnosis. Medicine has changed profoundly over the past century, not only through scientific discovery but also through increasing clinical specialization. Rather than being recognized as manifestations of a single syndrome, patients presenting with the characteristic combination of pathological sleep-wake disturbance, movement abnormalities, autonomic dysfunction, cognitive impairment, behavioural change, speech difficulty, swallowing impairment, and prolonged post-infectious disability would likely be evaluated by multiple specialists working within separate diagnostic frameworks. Each clinician might accurately identify one aspect of the illness while never recognizing the broader clinical pattern described during the original epidemic (Institute of Medicine, 2015; Bateman et al., 2021; National Academies of Sciences, Engineering, and Medicine, 2024).

This evolution reflects one of modern medicine’s greatest strengths. Specialization has transformed neurological care through advances in neuroimaging, autonomic testing, sleep medicine, molecular immunology, rehabilitation, and precision diagnostics. At the same time, increasingly specialized care can make it more difficult to recognize diseases that span multiple physiological systems. Infection-associated chronic conditions illustrate this challenge particularly well. Patients frequently accumulate diagnoses such as ME/CFS, POTS, dysautonomia, mast cell activation syndrome, small fiber neuropathy, gastrointestinal dysmotility, central hypersomnia, cognitive impairment, functional neurological disorder, anxiety, depression, or post-viral syndrome. Each diagnosis may accurately describe one manifestation of illness while providing only a partial explanation for the patient’s overall clinical presentation (Komaroff and Lipkin, 2023; Dani et al., 2021; Davis et al., 2023; Peluso et al., 2022).

Historical descriptions suggest that encephalitis lethargica represented precisely this type of multisystem illness. Contemporary physicians documented disturbances of consciousness, sleep, movement, speech, swallowing, behaviour, autonomic regulation, ocular function, cognition, and prolonged neurological disability as components of one syndrome because neurology had not yet fragmented into the subspecialties that exist today (von Economo, 1929; Bassoe, 1919; Hall, 1924; Foley, 2009). Modern medicine has substantially improved diagnostic precision within each of these domains, yet the same advances may also make it more difficult to recognize when these manifestations arise from a common biological process.

A Modern Diagnostic Journey

A patient presenting today with the classical features of encephalitis lethargica would likely follow a very different diagnostic pathway than a patient seen during the early twentieth century. Excessive daytime sleepiness might prompt referral to sleep medicine, where polysomnography and multiple sleep latency testing could identify idiopathic hypersomnia, central hypersomnia, or narcolepsy-like syndromes. Tremor, rigidity, bradykinesia, gait disturbance, or impaired motor initiation would likely be evaluated by a movement disorder specialist. Orthostatic symptoms could lead to autonomic testing and diagnoses such as POTS or orthostatic intolerance, while persistent tachycardia or syncope might initially be managed within cardiology.

Cognitive dysfunction could be described as executive dysfunction, attention impairment, or mild neurocognitive disorder, whereas feeding difficulty might be attributed to dysphagia, gastrointestinal dysmotility, autonomic dysfunction, or nutritional compromise. Environmental sensitivity could eventually prompt evaluation for mast cell activation syndrome or multiple chemical sensitivity. If disabling post-exertional symptom exacerbation became the dominant feature, many patients would ultimately receive diagnoses such as ME/CFS or Long COVID depending on the timing and documented trigger of the original infection (Institute of Medicine, 2015; Dani et al., 2021; Bateman et al., 2021; Davis et al., 2023; National Academies of Sciences, Engineering, and Medicine, 2024).

The striking observation is not that any of these diagnoses would necessarily be incorrect. Rather, they represent different clinical perspectives on what may be one interconnected neuroimmune illness. Physicians caring for patients during the encephalitis lethargica epidemic lacked the scientific tools to distinguish autonomic dysfunction from altered consciousness, immune dysregulation from psychiatric disease, or pathological hypersomnolence from generalized fatigue. Modern clinicians possess those tools but often encounter the opposite challenge. Increasing diagnostic precision within individual organ systems can obscure the larger syndrome connecting them. Patients may therefore accumulate multiple accurate diagnoses without anyone asking whether these disorders collectively reconstruct a phenotype already described more than a century ago.

Reconstructing a Historical Phenotype

This perspective becomes particularly compelling when historical case descriptions are compared with severe ME/CFS and neurological Long COVID. Reports of patients trapped between sleep and wakefulness resemble modern descriptions of central hypersomnolence, severe sleep inertia, and disorders of arousal. Historical accounts of apparent paralysis with preserved awareness parallel descriptions from patients with very severe ME/CFS who remain cognitively intact despite profound motor limitation and minimal outward responsiveness. Tremor, rigidity, dysphagia, impaired speech, autonomic instability, cognitive dysfunction, sensory intolerance, and prolonged disability now appear repeatedly throughout the modern literature, although they are frequently distributed across multiple diagnostic categories rather than recognized as components of one syndrome (Bateman et al., 2021; Davis et al., 2023; Martínez-Salio et al., 2024; Morelli-Zaher et al., 2024; Fernández-Castañeda et al., 2024).

No individual symptom establishes continuity between encephalitis lethargica and modern infection-associated chronic disease. Sleep disorders, movement abnormalities, autonomic dysfunction, or cognitive impairment each occur in numerous neurological conditions. The strength of the comparison instead lies in the constellation of findings. Historical encephalitis lethargica consistently combined pathological sleep-wake disturbance, motor dysfunction, behavioural or cognitive change, autonomic abnormalities, impaired communication, swallowing dysfunction, and prolonged post-infectious disability within the same patient. That multidomain phenotype now appears across severe infection-associated neuroimmune disease far more often than would be expected if the similarities reflected coincidence alone (Komaroff and Lipkin, 2023; National Academies of Sciences, Engineering, and Medicine, 2024).

Viewing encephalitis lethargica through this modern lens also helps explain why the syndrome has remained difficult to classify. It does not fit comfortably within traditional neurological, infectious disease, psychiatric, or rehabilitation frameworks because it occupies the intersection of all of them. Modern infection-associated chronic conditions increasingly occupy that same intersection. Rather than representing isolated diseases, they may describe different clinical expressions of a shared neuroimmune response shaped by pathogen, host susceptibility, immune regulation, genetics, environmental exposures, and the specific neural networks affected. This interpretation does not eliminate important differences among these conditions, but it provides a coherent biological framework capable of accommodating both their similarities and their diversity (Peluso et al., 2022; Pretorius et al., 2022; Fernández-Castañeda et al., 2024).

From Historical Description to a Testable Phenotype

Reconstructing encephalitis lethargica as a modern clinical phenotype transforms the discussion from historical speculation into a testable scientific hypothesis. Rather than attempting to retrospectively diagnose individual patients who lived more than a century ago, investigators can ask whether contemporary patients satisfy the defining clinical characteristics repeatedly documented by von Economo, Bassoe, Hall, and other physicians who cared for the original epidemic. This shifts the focus away from historical labels and toward measurable phenotypic overlap.

The critical question is therefore no longer whether encephalitis lethargica “was” ME/CFS or Long COVID. Instead, it is whether modern infection-associated chronic disease contains a reproducible subgroup whose combined neurological, autonomic, sleep-related, and functional characteristics closely mirror the historical syndrome. Contemporary medicine now possesses standardized neurological examinations, validated autonomic testing, sleep studies, advanced neuroimaging, immunophenotyping, longitudinal clinical datasets, and international patient registries that make this question scientifically testable rather than purely historical (Institute of Medicine, 2015; Bateman et al., 2021; Davis et al., 2023; National Academies of Sciences, Engineering, and Medicine, 2024).

The availability of these tools fundamentally changes the discussion. For the first time since encephalitis lethargica was described, it is possible to move beyond historical interpretation and ask whether the defining phenotype continues to exist within contemporary patient populations. That possibility leads naturally to a question that has received remarkably little scientific attention despite more than a century of investigation: if the historical phenotype persists, how many people today might satisfy its defining clinical characteristics?

9. A Question Medicine Has Never Asked: How Many People Today Fit the Historical Encephalitis Lethargica Phenotype?

For more than a century, research on encephalitis lethargica has focused almost exclusively on determining what caused the original epidemic. Influenza, streptococcal infection, enteroviruses, autoimmune disease, persistent infection, toxic exposures, nutritional deficiencies, and numerous additional hypotheses have each contributed important insights, yet no single explanation has fully resolved the historical mystery (Foley, 2009; Mortimer, 2009; Hoffman and Vilensky, 2017; Brainin, Teuschl and Gelpi, 2024). Far less attention has been directed toward a different and potentially more consequential question. If the defining clinical phenotype never disappeared, how many people might be living with it today under different diagnostic names?

Until recently, answering that question would have been nearly impossible. Although ME/CFS research established that infections could trigger prolonged neurological, autonomic, cognitive, and sleep-related illness, the disease remained substantially underdiagnosed, lacked consistent international surveillance, and was rarely studied at a population level (Institute of Medicine, 2015; Komaroff and Lipkin, 2023). Earlier outbreaks associated with Epstein-Barr virus, enteroviruses, Q fever, Ross River virus, SARS-CoV-1, Ebola virus, and other infections generated valuable longitudinal cohorts, but none produced a sufficiently large and systematically characterized patient population to permit reconstruction of a historical neurological phenotype on a global scale (Hickie et al., 2006; Chia and Chia, 2008; Lam et al., 2009; Moldofsky and Patcai, 2011; Wilson et al., 2018).

The COVID-19 pandemic fundamentally changed that landscape. Long COVID has produced the largest documented population of persistent post-infectious illness in modern history, creating an unprecedented opportunity to examine severe neuroimmune phenotypes across millions of patients. Recent estimates suggest that approximately 400 million people worldwide have experienced Long COVID, with annual economic costs approaching one trillion U.S. dollars. Although prevalence estimates vary according to case definition, follow-up duration, reinfection, vaccination status, age, and methods of ascertainment, the pandemic has created a sufficiently large denominator to investigate whether relatively uncommon neurological phenotypes may still affect millions of individuals worldwide (Davis et al., 2021; Davis et al., 2023; Al-Aly et al., 2024; Hou et al., 2025).

Importantly, Long COVID has also reproduced several neurological features once considered unusually characteristic of encephalitis lethargica. Sleep medicine cohorts have documented excessive daytime sleepiness, idiopathic hypersomnia, central hypersomnia, narcolepsy-like syndromes, severe sleep inertia, and disorders of arousal following SARS-CoV-2 infection. In specialized post-COVID clinics, patients have undergone polysomnography, actigraphy, and multiple sleep latency testing demonstrating objective abnormalities extending well beyond generalized fatigue (Coelho et al., 2024; Morelli-Zaher et al., 2024). These observations suggest that pathological disturbances of sleep and wakefulness remain measurable components of contemporary post-infectious disease.

Movement disorders provide another point of convergence. Published reports have described rigidity, bradykinesia, tremor, postural instability, hypomimia, hypophonia, gait disturbance, myoclonus, and encephalopathy accompanied by parkinsonism following COVID-19. A recent scoping review identified twenty-six reported cases across seventeen publications, categorizing patients into distinct post-infectious movement phenotypes while emphasizing that current evidence remains insufficient to infer population-wide Parkinson’s disease risk (Ali et al., 2022; Cavallieri et al., 2022; Makhoul et al., 2023; Polverino et al., 2024). Although uncommon, these reports demonstrate that modern post-infectious illness can reproduce neurological syndromes historically regarded as defining characteristics of encephalitis lethargica.

These observations highlight an important methodological principle. The contemporary prevalence of an encephalitis lethargica phenotype cannot be estimated by counting isolated symptoms such as fatigue, tremor, hypersomnolence, or cognitive dysfunction independently. Each occurs across numerous neurological and medical disorders and would produce an implausibly broad estimate if considered alone. Instead, prevalence should be based upon the simultaneous occurrence of a historically meaningful constellation of features involving pathological sleep-wake dysfunction, movement impairment, cognitive or behavioural disturbance, autonomic dysfunction, and sustained post-infectious disability. The defining feature of encephalitis lethargica was never a single symptom. It was the convergence of multiple neurological domains within the same patient (von Economo, 1929; Hall, 1924; Foley, 2009; Brainin, Teuschl and Gelpi, 2024).

To preserve both historical fidelity and clinical specificity, prevalence estimation should employ nested phenotype definitions rather than a single diagnostic threshold. A classical phenotype would prioritize pathological sleep-wake dysfunction together with major movement, ocular motor, speech, swallowing, or consciousness abnormalities. An intermediate phenotype would identify patients demonstrating severe disturbances of arousal, impaired motor initiation, preserved awareness despite markedly reduced responsiveness, and chronic post-infectious disability. A broader phenotype would capture individuals with substantial impairment across multiple historical domains while acknowledging the biological heterogeneity recognized throughout the original epidemic. Presenting prevalence as a range rather than a single value more accurately reflects both the historical literature and the complexity of contemporary infection-associated chronic disease.

Reliable estimation will ultimately require individual-level datasets rather than aggregated symptom frequencies. Published prevalence studies generally report fatigue, sleep disturbance, dysautonomia, cognitive impairment, mobility limitation, tremor, dysphagia, or sensory symptoms independently, but these manifestations are neither statistically independent nor uniformly distributed across patient populations. Simply adding or multiplying symptom frequencies would therefore produce misleading estimates. Individual-level clinical data allow investigators to determine how frequently defining characteristics occur within the same patient, distinguish transient symptoms from persistent neurological disability, and account for symptom clustering that cannot be reconstructed from summary statistics alone (Davis et al., 2021; Davis et al., 2023).

International representation will be equally important. Long COVID prevalence differs substantially across countries because of variation in testing availability, reinfection, vaccination, viral variants, healthcare access, diagnostic criteria, demographic characteristics, and recognition of chronic illness. Restricting analyses to highly specialized North American or European clinics would likely overrepresent patients with access to advanced neurological evaluation while underestimating disease prevalence in lower-resource settings. A globally representative model should therefore incorporate cohorts from multiple geographic regions and healthcare systems to improve generalizability and reduce ascertainment bias (World Health Organization, 2021; Chen et al., 2022; Hou et al., 2025).

Even before such analyses are completed, simple threshold scenarios illustrate the potential scale of the question. Using a cumulative global Long COVID population of approximately 400 million individuals, a strict encephalitis lethargica-compatible phenotype affecting only 0.5% of patients would represent roughly two million people worldwide. A prevalence of 1% would correspond to approximately four million individuals, while 2.5% would approach ten million. These values are not proposed as prevalence estimates but as demonstrations that even a rare phenotype within Long COVID could produce a contemporary population comparable to or exceeding historical estimates of the original encephalitis lethargica epidemic (Al-Aly et al., 2024; Brainin, Teuschl and Gelpi, 2024).

Preliminary Contemporary Prevalence Scenarios

The proposed encephalitis lethargica-compatible phenotype can be illustrated using the updated 2026 US-CCUC™ estimates for infection-associated chronic conditions (IACCs). These calculations are not intended to estimate the prevalence of encephalitis lethargica itself. Rather, they demonstrate the potential prevalence of a historically compatible neuroimmune phenotype within the broader IACC population. Definitive estimates will require standardized phenotype definitions and validation using individual-level datasets.

United States IACC Scenario

The 2026 US-CCUC™ model estimates 75-90 million Americans living with at least one infection-associated chronic condition, including Long COVID, ME/CFS, dysautonomia, post-treatment Lyme disease syndrome, and related post-infectious disorders. Within this population, approximately 25-35 million individuals are estimated to experience multiple overlapping IACCs, reflecting the substantial biological convergence observed across these conditions.

Formula Estimated U.S. IACC Population × EL-Compatible Phenotype = Estimated Contemporary EL-Compatible Population

United States  Prevalence Encephalitis Lethargic Estimate 2026

EL-Compatible Phenotype	75 Million	90 Million
0.5%	375,000	450,000
1.0%	750,000	900,000
2.5%	1.88 million	2.25 million

Even under the most conservative assumptions, a phenotype compatible with historical descriptions of encephalitis lethargica would represent several hundred thousand Americans. At moderate thresholds, the affected population approaches one million individuals, while broader but still restrictive scenarios exceed two million.

US-CCUC-R™ Prevalence Encephalitis Lethargic Estimate 2026

Race/Ethnicity	US-CCUC-R™ Share	Estimated EL-Compatible Population
White (Non-Hispanic)	55–60%	413k–540k
Black / African American	15–20%	113k–180k
Hispanic / Latine	12–15%	90k–135k
Asian American / Pacific Islander	5–8%	38k–72k
Native American / Alaska Native	3–4%	23k–36k
Multiracial / Other	3–5%	23k–45k

Note: Demographic estimates apply the previously published US-CCUC-R™ race-adjustment framework to the estimated national EL-compatible phenotype. They are intended for planning and hypothesis generation and should not be interpreted as directly observed prevalence.

Global IACC Scenario

Applying the same framework to CYNAERA’s estimated global infection-associated chronic condition population of 2.8-4.6 billion people illustrates the potential worldwide prevalence.

Formula Estimated Global IACC Population × EL-Compatible Phenotype = Estimated Global EL-Compatible Population

Global Prevalence Encephalitis Lethargic Estimate 2026

EL-Compatible Phenotype	2.8 Billion	4.6 Billion
0.5%	14 million	23 million
1.0%	28 million	46 million
2.5%	70 million	115 million

These scenarios demonstrate that even an uncommon neuroimmune phenotype could affect tens of millions of people worldwide when evaluated across the broader spectrum of infection-associated chronic conditions.

Interpreting the Two Models

The United States and global models answer complementary questions. The U.S. estimate illustrates the potential national prevalence using the updated US-CCUC™ framework, providing a planning estimate relevant to healthcare delivery, surveillance, and policy. The global estimate explores the potential scale of the same phenotype across the worldwide IACC population, recognizing that chronic post-infectious illness has been documented following numerous infectious diseases, including SARS-CoV-2, Epstein-Barr virus, enteroviruses, influenza, Q fever, Lyme disease, chikungunya, and Ebola virus.

Neither model estimates the prevalence of encephalitis lethargica itself. Instead, both estimate the potential prevalence of a modern clinical phenotype that closely resembles the syndrome historically described during the encephalitis lethargica epidemic. If future studies identify a comparable phenotype within contemporary IACC cohorts, encephalitis lethargica may be better understood not as a vanished disease, but as one severe expression of a recurring infection-associated neuroimmune architecture.

For more than a century, medicine has asked what caused encephalitis lethargica. Advances in Long COVID research now make it possible to ask an equally important question: how many people living today satisfy the historical clinical phenotype of this supposedly vanished disease? Answering that question will not determine whether encephalitis lethargica, ME/CFS, and Long COVID are identical disorders. It will determine whether one of medicine’s oldest unresolved neurological syndromes continues to exist as a measurable phenotype embedded within contemporary infection-associated chronic disease.

10. Why This Matters: Implications for Research, Clinical Care, and Pandemic Preparedness

If the central hypothesis presented in this review is correct, its implications extend well beyond the historical interpretation of encephalitis lethargica. This is not simply a debate about a neurological epidemic that occurred more than one hundred years ago. It is a question about how medicine recognizes chronic disease, organizes biomedical research, and prepares for the long-term consequences of infectious outbreaks. If encephalitis lethargica represents one severe expression of a recurring infection-associated neuroimmune phenotype, then the lessons documented during the early twentieth century remain directly relevant to contemporary medicine and future pandemics.

Over the past century, biomedical science has transformed our understanding of post-infectious illness. Conditions once viewed as isolated syndromes are increasingly recognized as part of broader biological networks involving immune dysregulation, autonomic dysfunction, endothelial injury, neurovascular abnormalities, altered brain connectivity, metabolic impairment, and persistent inflammatory signaling (Komaroff and Lipkin, 2023; Peluso et al., 2022; Fernández-Castañeda et al., 2024; National Academies of Sciences, Engineering, and Medicine, 2024). Reconsidering encephalitis lethargica within this expanding scientific framework does not diminish the importance of its historical context. Instead, it suggests that one of medicine’s oldest neurological mysteries may contribute directly to understanding some of its newest.

Implications for Biomedical Research

Perhaps the most immediate implications involve biomedical research. Historically, investigations of ME/CFS, Long COVID, dysautonomia, post-infectious movement disorders, hypersomnolence, autoimmune encephalitis, and related conditions have largely evolved within separate scientific communities. Each discipline has generated important discoveries, yet relatively few studies have examined how these findings intersect across diseases. As a result, similar biological processes, including persistent infection or antigen exposure, immune dysregulation, neuroinflammation, endothelial dysfunction, autonomic instability, mitochondrial impairment, and altered neurotransmission, are often investigated repeatedly under different diagnostic labels rather than collectively as components of a broader host-response biology (Chia and Chia, 2008; Proal and VanElzakker, 2021; Komaroff and Lipkin, 2023; Davis et al., 2023; Peluso et al., 2022).

A phenotype-based framework encourages a different approach. Rather than beginning with established diagnostic categories, investigators can identify patients who share common biological and clinical characteristics despite differing infectious triggers. This strategy has become increasingly common in oncology, immunology, and molecular medicine, where diseases are now routinely classified according to genetic alterations, signaling pathways, and immune characteristics rather than organ location alone (National Research Council, 2011; Ashley, 2016). Infection-associated chronic conditions may similarly benefit from research strategies that prioritize shared biological mechanisms while continuing to recognize disease-specific differences.

Such an approach also creates opportunities for collaboration that have historically been limited by diagnostic boundaries. Discoveries in Long COVID may inform ME/CFS research, while advances in autonomic medicine, sleep science, vascular biology, movement disorders, neuroimmunology, and systems neuroscience may each contribute to a more comprehensive understanding of chronic post-infectious illness. Instead of competing for attention as separate disorders, these conditions can be investigated as overlapping expressions of infection-associated neuroimmune disease, allowing findings from one field to accelerate progress across many others (Institute of Medicine, 2015; Komaroff and Lipkin, 2023; National Academies of Sciences, Engineering, and Medicine, 2024).

Implications for Clinical Care

Clinical medicine may benefit equally from a phenotype-centered perspective. Advances in specialization have transformed patient care by allowing physicians to develop extraordinary expertise within individual organ systems. Yet patients with infection-associated chronic illness frequently experience neurological, cardiovascular, immunological, gastrointestinal, endocrine, and sleep-related manifestations simultaneously. Each symptom may be evaluated appropriately within its respective specialty, while the broader disease process connecting those findings remains difficult to recognize.

A patient may therefore receive diagnoses of POTS, ME/CFS, mast cell activation syndrome, gastrointestinal dysmotility, hypersomnolence, tremor, cognitive impairment, migraine, or anxiety following infection. None of these diagnoses is necessarily incorrect. Together, however, they may describe different manifestations of one interconnected neuroimmune illness rather than multiple unrelated disorders. Recognizing this possibility does not replace existing diagnostic categories. Instead, it provides clinicians with a broader framework for understanding why these conditions frequently coexist and why multidisciplinary care has become increasingly important for patients with complex post-infectious disease (Dani et al., 2021; Bateman et al., 2021; Komaroff and Lipkin, 2023; Davis et al., 2023).

This perspective also aligns naturally with precision medicine. Rather than assuming that every patient carrying the same diagnosis shares identical biology, precision medicine seeks to identify the specific mechanisms driving disease in each individual. Patients with evidence of persistent viral antigen may require different therapeutic strategies than those whose illness is dominated by autoimmunity, mast cell activation, endothelial dysfunction, autonomic instability, mitochondrial impairment, or metabolic abnormalities. Conversely, patients assigned different diagnostic labels may ultimately benefit from similar therapies when they share common biological pathways. This shift from disease-centered treatment toward mechanism-centered treatment has already transformed oncology, rheumatology, and immunology and may represent the next major step in the management of infection-associated chronic disease (National Research Council, 2011; Ashley, 2016; Komaroff and Lipkin, 2023).

Implications for Public Health and Pandemic Preparedness

The COVID-19 pandemic demonstrated that the long-term consequences of infection can persist long after the acute public health emergency has ended. Although pandemic preparedness has traditionally emphasized limiting transmission, reducing mortality, preserving healthcare capacity, and accelerating vaccine and therapeutic development, Long COVID has revealed that chronic disability represents an equally important component of pandemic impact. Millions of individuals continue to experience persistent neurological, cardiovascular, immunological, and functional impairment years after their initial infection, creating substantial consequences for healthcare systems, employment, education, caregiving, and economic productivity (World Health Organization, 2021; Davis et al., 2023; Al-Aly et al., 2024; National Academies of Sciences, Engineering, and Medicine, 2024).

Viewed within a broader historical context, these outcomes appear less unprecedented than once believed. Post-infectious neurological syndromes have followed influenza, Epstein-Barr virus, enteroviruses, Q fever, Ebola virus, chikungunya, SARS-CoV-1, and numerous other infectious diseases, while encephalitis lethargica remains one of the most dramatic examples of widespread post-infectious neurological disability ever documented (Hickie et al., 2006; Wilson et al., 2018; Nalbandian et al., 2023; Brainin, Teuschl and Gelpi, 2024). Long COVID therefore represents not the beginning of chronic post-infectious illness, but the largest modern opportunity to study it systematically.

If severe infection-associated neuroimmune phenotypes have repeatedly emerged following major infectious outbreaks, then they should no longer be regarded as rare or unexpected complications. Instead, they should be anticipated as part of comprehensive pandemic planning. Surveillance systems should extend beyond acute infection to include long-term neurological, autonomic, cognitive, and functional outcomes. Investment in rehabilitation, autonomic medicine, neuroimmune research, longitudinal patient registries, and post-infectious specialty clinics should likewise become integral components of preparedness planning rather than reactive responses developed only after large numbers of chronically ill patients have already appeared (World Health Organization, 2021; National Academies of Sciences, Engineering, and Medicine, 2024; Al-Aly et al., 2024).

This broader perspective also has implications for epidemiology. Public health surveillance has traditionally measured infections, hospitalizations, mortality, and short-term recovery. Chronic post-infectious disability has received comparatively less attention despite its substantial effects on quality of life, workforce participation, healthcare utilization, and long-term economic prevalence. Incorporating standardized surveillance for infection-associated chronic conditions would provide a more complete understanding of pandemic impact while improving resource allocation, research prioritization, and healthcare planning for future outbreaks.

Implications for Patients

The implications extend beyond research and public health. For generations, patients with post-infectious illness have described profound exhaustion, pathological sleep disturbances, cognitive dysfunction, autonomic instability, movement abnormalities, sensory intolerance, fluctuating neurological impairment, and prolonged disability despite relatively limited findings on conventional diagnostic testing. Many experienced prolonged diagnostic delays or were told that their symptoms reflected stress, anxiety, deconditioning, or psychological illness rather than underlying biological disease. Similar patterns appear repeatedly throughout the histories of encephalitis lethargica, ME/CFS, and Long COVID despite occurring nearly a century apart (Institute of Medicine, 2015; Komaroff and Lipkin, 2023; Davis et al., 2023; National Academies of Sciences, Engineering, and Medicine, 2024).

Reexamining encephalitis lethargica through the lens of modern neuroimmunology therefore does more than refine disease classification. It restores continuity across generations of patients whose illnesses have often been separated by changing terminology rather than fundamentally different biology. Although individual diagnoses remain clinically important, recognizing recurring neuroimmune patterns encourages medicine to ask broader questions about shared mechanisms instead of assuming that each new post-infectious syndrome represents an entirely new disease.

This perspective may also reduce fragmentation experienced by many patients navigating modern healthcare. Individuals living with complex infection-associated chronic illness frequently move among multiple specialists, accumulating accurate but disconnected diagnoses that describe isolated organ systems rather than the biological processes linking them. A more integrated framework does not eliminate disciplinary expertise. Instead, it complements specialty care by encouraging clinicians and researchers to consider how neurological, autonomic, vascular, immune, metabolic, and sleep-related dysfunction interact within the same patient.

A Broader Scientific Question

Ultimately, the hypothesis presented in this review is not that encephalitis lethargica has been definitively explained. Rather, it suggests that the historical question itself may require reframing. For more than one hundred years, investigators have searched for the pathogen responsible for the original epidemic. That search has generated invaluable scientific insights, yet it has not fully resolved why encephalitis lethargica produced such remarkable clinical diversity or why comparable neurological syndromes continue to appear after a wide range of infections.

The evidence reviewed throughout this paper suggests another possibility. Medicine may have repeatedly encountered severe infection-associated neuroimmune phenotypes across successive generations while describing them according to the dominant scientific language of each era. If that interpretation is correct, encephalitis lethargica belongs not only to the history of neurology but also to the continuing evolution of infection-associated chronic disease. Its greatest contribution may therefore lie not simply in understanding a vanished epidemic, but in helping modern medicine recognize recurring biological patterns that continue to shape the lives of patients today.

11. Limitations

Like any historical reinterpretation, the hypothesis presented in this review should be considered within the context of several important limitations. The objective is not to retrospectively diagnose individual patients who lived more than one hundred years ago, nor to argue that every historical case of encephalitis lethargica would satisfy modern diagnostic criteria for ME/CFS or Long COVID. Such conclusions extend beyond the available evidence. Instead, this review proposes that the historical encephalitis lethargica phenotype warrants systematic reexamination using contemporary advances in neuroimmunology, autonomic medicine, sleep science, systems neuroscience, and infection-associated chronic disease research.

The historical medical record is necessarily incomplete. Physicians caring for patients during the encephalitis lethargica epidemic documented their observations with extraordinary clinical detail, yet they practiced decades before the development of concepts now central to infection-associated chronic disease, including post-exertional malaise, orthostatic intolerance, postural orthostatic tachycardia syndrome, cerebral hypoperfusion, mast cell activation syndrome, central disorders of hypersomnolence, endothelial dysfunction, viral persistence, and many of the immunological mechanisms currently under investigation. Consequently, the absence of these findings from historical reports should not be interpreted as evidence that the underlying biological processes were absent. Rather, it reflects the scientific framework and diagnostic capabilities available at the time (Bassoe, 1919; Hall, 1924; Institute of Medicine, 2015; Komaroff and Lipkin, 2023; National Academies of Sciences, Engineering, and Medicine, 2024).

Biological heterogeneity represents a second important limitation. Historical descriptions demonstrate considerable variation in clinical presentation, disease severity, progression, pathology, and long-term outcome, suggesting that encephalitis lethargica was unlikely to represent a completely homogeneous disorder. Modern investigations similarly support multiple potential mechanisms, including post-infectious autoimmunity, persistent infection or antigen exposure, neuroinflammation, endothelial dysfunction, and other pathways that remain incompletely understood (Dale et al., 2004; Hoffman and Vilensky, 2017; Brainin, Teuschl and Gelpi, 2024). Comparable heterogeneity is now well recognized across both ME/CFS and Long COVID, where accumulating evidence suggests multiple biological subtypes rather than a single uniform disease process (Komaroff and Lipkin, 2023; Davis et al., 2023; Peluso et al., 2022; National Academies of Sciences, Engineering, and Medicine, 2024).

Accordingly, this review does not propose that all patients with ME/CFS or Long COVID exhibit an encephalitis lethargica phenotype. Both conditions encompass a broad spectrum of severity and clinical presentation. Many patients would demonstrate little overlap with historical descriptions, whereas others may share substantial similarities across neurological, autonomic, sleep-wake, motor, cognitive, and behavioural domains. The proposed phenotype should therefore be regarded as one potential subgroup within the broader landscape of infection-associated chronic conditions rather than as a replacement for existing diagnostic categories.

Phenotypic similarity also should not be interpreted as proof of identical pathophysiology. Different pathogens may produce overlapping downstream immune responses, while similar clinical manifestations can arise through distinct biological mechanisms. Conversely, patients infected with the same microorganism may experience markedly different long-term outcomes depending upon host genetics, immune regulation, age, sex, environmental exposures, comorbidities, reinfection history, and other biological factors. The hypothesis advanced in this review is therefore one of biological convergence rather than biological identity, emphasizing shared neuroimmune architecture without assuming a single universal mechanism.

The prevalence framework proposed in this paper likewise requires prospective validation. Reliable estimation of a contemporary encephalitis lethargica-compatible phenotype will depend upon standardized clinical criteria, individual-level datasets, and longitudinal cohorts capable of identifying the simultaneous occurrence of defining neurological features within the same patient. Published symptom frequencies alone cannot provide accurate prevalence estimates because they do not account for symptom clustering, referral bias, healthcare access, international differences in case ascertainment, or overlap among existing diagnostic categories.

Future studies should therefore evaluate the proposed phenotype using harmonized international datasets and reproducible case definitions before drawing epidemiological conclusions. Despite these limitations, the central hypothesis is now scientifically testable in ways that were impossible throughout most of the past century. Contemporary medicine possesses tools unavailable to von Economo, Bassoe, Hall, and their colleagues, including advanced neuroimaging, autonomic testing, immunophenotyping, cerebrospinal fluid analysis, wearable physiological monitoring, longitudinal electronic health records, molecular pathology, and large international patient registries. These advances allow investigators to move beyond historical interpretation and directly evaluate whether contemporary patients with severe ME/CFS, neurological Long COVID, and related infection-associated chronic conditions reproduce the defining phenotype historically associated with encephalitis lethargica. The question is no longer beyond the reach of science. It has become an empirically testable hypothesis.

12. Conclusion

For more than one hundred years, encephalitis lethargica has remained one of medicine’s greatest unresolved neurological mysteries. The prevailing scientific question has focused on identifying the pathogen responsible for the epidemic. Influenza, enteroviruses, streptococcal infection, autoimmune mechanisms, and numerous other hypotheses have each contributed valuable insight, yet none has fully explained the extraordinary clinical diversity of the original epidemic or the sporadic EL-like syndromes that continue to appear in modern medicine (Bassoe, 1919; Dale et al., 2004; Hoffman and Vilensky, 2017; Brainin, Teuschl and Gelpi, 2024).

This review proposes that the enduring mystery may have been framed too narrowly. Rather than asking only which pathogen initiated the epidemic, it asks whether the defining clinical phenotype ever truly disappeared. Historical descriptions of profound sleep-wake dysfunction, movement abnormalities, autonomic instability, cognitive impairment, behavioural change, preserved awareness despite severe motor limitation, fluctuating neurological disability, and prolonged post-infectious illness demonstrate substantial convergence with severe ME/CFS and neurological Long COVID when interpreted through the lens of contemporary neuroimmunology, autonomic medicine, sleep science, and infection-associated chronic disease research (Institute of Medicine, 2015; Komaroff and Lipkin, 2023; Davis et al., 2023; National Academies of Sciences, Engineering, and Medicine, 2024).

The hypothesis presented here is intentionally conservative. It does not argue that encephalitis lethargica, ME/CFS, and Long COVID are interchangeable diagnoses, nor that every patient with a modern infection-associated chronic condition represents a contemporary case of encephalitis lethargica. Instead, the evidence supports a broader possibility: these disorders may occupy overlapping positions within a recurring spectrum of infection-associated neuroimmune disease. If that interpretation proves correct, then the apparent disappearance of encephalitis lethargica may reflect changes in medical terminology, scientific understanding, and diagnostic classification more than the disappearance of the underlying biological phenotype itself.

Viewing encephalitis lethargica through this broader framework has implications that extend well beyond medical history. It encourages investigators to organize research around shared biological mechanisms rather than isolated disease labels, supports precision medicine approaches that prioritize underlying pathophysiology over historical nomenclature, and reinforces the importance of integrating neurology, immunology, autonomic medicine, sleep science, vascular biology, rehabilitation, and infectious disease when investigating chronic post-infectious illness. It also provides a practical framework for addressing a question that has remained largely unexplored since the original epidemic: whether the historical encephalitis lethargica phenotype persists within contemporary populations living with severe infection-associated chronic disease.

History repeatedly demonstrates that medicine advances by revisiting old observations with new scientific tools. Diseases once believed to be distinct are sometimes recognized as biologically related, while apparently uniform diseases are later understood to represent multiple mechanisms or subtypes. Encephalitis lethargica deserves the same careful reconsideration. For the first time since von Economo and his contemporaries documented the original epidemic, advances in molecular biology, neuroimmunology, systems neuroscience, autonomic medicine, computational analysis, and large international patient cohorts make it possible to evaluate this hypothesis directly rather than relying solely on historical interpretation.

Perhaps the greatest mystery surrounding encephalitis lethargica is not why it disappeared, but whether medicine ever recognized that it never did.

How to Cite

Adinig, C. (2026, July). Encephalitis lethargica: The biggest medical mystery of the 20th century may not be history: Reexamining encephalitis lethargica in the era of ME/CFS and Long COVID. CYNAERA. https://www.cynaera.com/post/Encephalitis-Lethargica

Frequently Asked Questions for Encephalitis Lethargica

Did encephalitis lethargica disappear?

No. This paper concludes that the encephalitis lethargica phenotype persists but is now distributed across modern diagnoses rather than recognized as a single disease entity. Advances in neurology, immunology, and infectious disease have divided patients into categories such as ME/CFS, Long COVID, autoimmune encephalitis, dysautonomia, movement disorders, hypersomnia syndromes, and other infection-associated chronic conditions.

Is encephalitis lethargica the same as ME/CFS or Long COVID?

Not exactly. This paper concludes that encephalitis lethargica did not disappear. Instead, the historical syndrome was redistributed across multiple modern diagnoses, including ME/CFS, Long COVID, autoimmune encephalitis, dysautonomia, movement disorders, and hypersomnia syndromes. These diagnoses describe different clinical presentations, but many patients may express the same underlying encephalitis lethargica-compatible neuroimmune phenotype..

How many Americans have an encephalitis lethargica-compatible phenotype?

Using CYNAERA's 2026 U.S. IACC estimate of 75–90 million Americans, this paper estimates that 375,000–2.25 million Americans currently express an encephalitis lethargica-compatible phenotype. The central model estimates 750,000–900,000 people, representing approximately one percent of the contemporary IACC population.

How was the estimate calculated?

The estimate uses the following formula: Estimated U.S. IACC Population × EL-Compatible Phenotype Fraction = Estimated Contemporary EL-Compatible Population

Rather than estimating from the general U.S. population, the model identifies the proportion of Americans living with infection-associated chronic conditions who exhibit an encephalitis lethargica-compatible phenotype.

Why does this paper estimate prevalence by race and ethnicity?

Historical encephalitis lethargica literature, like much of the early ME/CFS literature, disproportionately reflected patients who reached specialty care rather than the full affected population. This paper applies the US-CCUC-R™ demographic framework to produce a more representative estimate of the contemporary EL-compatible population across racial and ethnic groups.

What is the paper's central conclusion?

The evidence presented supports a new interpretation of encephalitis lethargica: it is best understood not as a vanished twentieth-century disease, but as a recurring infection-associated neuroimmune phenotype that continues to appear under multiple modern diagnostic labels. The greatest mystery surrounding encephalitis lethargica is no longer why it disappeared, but why medicine failed to recognize its continued existence.

CYNAERA Framework Papers

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library,  ME/CFS Library, Lyme Library,  Autoimmune Library and CRISPR Remission Library are also in depth resources.

• Primary Chronic Trigger (PCT)™ 

• The Body First Trial Protocol™

• Long COVID Prevalence in U.S. Military

• Long COVID Prevalence in Congress

• ME/CFS Prevalence Needs a Reset

• Personalized CRISPR Remission™ for MECFS

• Why Drug Approval For ME/CFS Was Always A Setup

•  Environmental Triggers of ME/CFS Flares

• COVID-19 and Ebola: Pandemic Preparedness

• Corrected National Prevalence Estimates for (IACCs)

• VitalGuard™ Environmental Flare Risk Engine

• The Hidden Public Health Cost of AI Data Centers

• US-CCUC Influenza™: Post-Influenza Chronic Illness

• Personalized CRISPR Remission™ for Long COVID

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.

Licensing and Integration

CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.

About the Author 

Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.

Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey,  Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.

She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research  with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.

Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.

References

1. Alexander, G.E., DeLong, M.R. and Strick, P.L. (1986) ‘Parallel organization of functionally segregated circuits linking basal ganglia and cortex’, Annual Review of Neuroscience, 9, pp. 357-381.

2. Al-Aly, Z., et al. (2024) ‘Long COVID science, research priorities, and clinical implications’, Nature Medicine.

3. Ali, A., et al. (2022) ‘Parkinsonism following COVID-19: A systematic review’, Journal of Neurology.

4. Ashley, E.A. (2016) ‘Towards precision medicine’, Nature Reviews Genetics, 17(9), pp. 507-522.

5. Barnden, L.R., et al. (2015) ‘A brain MRI study of chronic fatigue syndrome’, NeuroImage: Clinical, 8, pp. 394-401.

6. Bassoe, P. (1919) ‘Epidemic encephalitis (“encephalitis lethargica”): Its symptomatology, pathology and treatment’, Journal of Nervous and Mental Disease.

7. Bateman, L., Bested, A.C., Bonilla, H.F., et al. (2021) ‘Myalgic encephalomyelitis/chronic fatigue syndrome: Essentials of diagnosis and management’, Mayo Clinic Proceedings.

8. Brainin, M., Teuschl, Y. and Gelpi, E. (2024) ‘Encephalitis lethargica: One hundred years later’, Journal of Neural Transmission.

9. Cavallieri, F., et al. (2022) ‘Post-COVID parkinsonism: Clinical characteristics and proposed mechanisms’, Movement Disorders Clinical Practice.

10. Chen, C., et al. (2022) ‘Global prevalence of post-COVID-19 condition: A systematic review and meta-analysis’, Journal of Infection.

11. Chia, J.K.S. and Chia, A.Y. (2008) ‘Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach’, Journal of Clinical Pathology, 61(1), pp. 43-48.

12. Coelho, F.M., et al. (2024) ‘Sleep disorders following COVID-19 infection’, Sleep Medicine.

13. Dale, R.C., Church, A.J., Surtees, R.A.H., et al. (2004) ‘Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity’, Brain, 127(1), pp. 21-33.

14. Dalmau, J. and Graus, F. (2018) ‘Antibody-mediated encephalitis’, New England Journal of Medicine, 378, pp. 840-851.

15. Dani, M., Dirksen, A., Taraborrelli, P., et al. (2021) ‘Autonomic dysfunction in long COVID’, Clinical Medicine, 21(1), pp. e63-e67.

16. da Mota Gomes, M. (2020) ‘Encephalitis lethargica: Lessons from the past’, Sleep Medicine.

17. Davis, H.E., Assaf, G.S., McCorkell, L., et al. (2021) ‘Characterizing Long COVID in an international cohort’, EClinicalMedicine, 38, 101019.

18. Davis, H.E., McCorkell, L., Vogel, J.M. and Topol, E.J. (2023) ‘Long COVID: Major findings, mechanisms and recommendations’, Nature Reviews Microbiology.

19. Fernández-Castañeda, A., et al. (2024) ‘Neurological consequences of COVID-19 and persistent neuroinflammation’, Cell.

20. Filippi, M., et al. (2012) ‘Gray matter damage in multiple sclerosis’, Nature Reviews Neurology.

21. Foley, P.B. (2009) ‘Encephalitis lethargica and the von Economo disease’, Brain.

22. Hall, A.J. (1924) Epidemic Encephalitis (Encephalitis Lethargica). Bristol: John Wright & Sons.

23. Hickie, I., Davenport, T., Wakefield, D., et al. (2006) ‘Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens’, BMJ, 333, p. 575.

24. Hoffman, L.A. and Vilensky, J.A. (2017) ‘Encephalitis lethargica: 100 years after the epidemic’, Brain.

25. Hou, Y., et al. (2025) ‘Global prevalence of Long COVID, its subtypes, and risk factors: An updated systematic review and meta-analysis’, Open Forum Infectious Diseases. doi: 10.1093/ofid/ofaf533.

26. Institute of Medicine (2015) Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press.

27. Klein, J., Wood, J., Jaycox, J.R., Dhodapkar, R.M., Lu, P., Gehlhausen, J.R., et al. (2023) ‘Distinguishing features of long COVID identified through immune profiling’, Nature, 623, pp. 139-148.

28. Komaroff, A.L. and Lipkin, W.I. (2023) ‘Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of Long COVID’, Nature Reviews Microbiology.

29. Lam, M.H.B., et al. (2009) ‘Mental morbidities and chronic fatigue after SARS’, Archives of Internal Medicine.

30. Makhoul, K., et al. (2023) ‘Parkinsonism after COVID-19: A scoping review’, Journal of Parkinson’s Disease.

31. Marshall, B.J. and Warren, J.R. (1984) ‘Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration’, The Lancet, 323(8390), pp. 1311-1315.

32. Martínez-Salio, A., et al. (2024) ‘Central disorders of hypersomnolence following SARS-CoV-2 infection’, Sleep Medicine.

33. Moldofsky, H. and Patcai, J. (2011) ‘Chronic widespread musculoskeletal pain, fatigue, depression and sleep disturbance following SARS’, BMC Neurology.

34. Morelli-Zaher, C., et al. (2024) ‘Objective sleep abnormalities in Long COVID’, Journal of Clinical Sleep Medicine.

35. Mortimer, P.P. (2009) ‘Was encephalitis lethargica a post-influenzal or some other phenomenon? Time to re-examine the problem’, Epidemiology and Infection, 137(4), pp. 449-455. doi: 10.1017/S0950268808001891.

36. Nalbandian, A., et al. (2023) ‘Post-acute sequelae of COVID-19’, Nature Medicine.

37. National Academies of Sciences, Engineering, and Medicine (2024) Long-Term Health Effects of COVID-19: Disability and Function Following SARS-CoV-2 Infection. Washington, DC: National Academies Press. doi: 10.17226/27756.

38. National Research Council (2011) Toward Precision Medicine. Washington, DC: National Academies Press.

39. Peluso, M.J., Deeks, S.G., Mustapic, M., Kapogiannis, D., Henrich, T.J., Lu, S., Goldberg, S.A., Hoh, R., Chen, J.Y., Martinez, E.O., Kelly, J.D., Martin, J.N. and Goetzl, E.J. (2022) ‘SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19’, Annals of Neurology, 91(6), pp. 772-781.

40. Polverino, P., et al. (2024) ‘Post-infectious movement disorders after COVID-19: A systematic review’, Movement Disorders.

41. Pretorius, E., et al. (2022) ‘Persistent clotting protein pathology in Long COVID’, Cardiovascular Diabetology.

42. Proal, A.D. and VanElzakker, M.B. (2021) ‘Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors’, Frontiers in Microbiology.

43. Renz-Polster, H. and Scheibenbogen, C. (2022) ‘Pathophysiology of ME/CFS’, Nature Reviews Disease Primers.

44. Rogers, J.P., et al. (2024) ‘Encephalitis lethargica: Current perspectives and future directions’, The Lancet Neurology.

45. Sacks, O. (1973) Awakenings. London: Duckworth.

46. Stein, S.R., et al. (2024) ‘SARS-CoV-2 infection and persistence throughout the human body’, Nature.

47. Sulzer, D., et al. (2020) ‘COVID-19 and possible links with Parkinson’s disease’, NPJ Parkinson’s Disease.

48. van Campen, C.M.C., Verheugt, F.W.A., Rowe, P.C. and Visser, F.C. (2020) ‘Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: A quantitative, controlled study using Doppler echography’, Clinical Neurophysiology Practice, 5, pp. 50-58. doi: 10.1016/j.cnp.2020.01.003.

49. van Campen, C.M.C., Rowe, P.C. and Visser, F.C. (2022) ‘Cerebral blood flow is reduced during tilt testing in ME/CFS’, Healthcare.

50. von Economo, C. (1929) Encephalitis Lethargica: Its Sequelae and Treatment. Translated by K.O. Newman. London: Oxford University Press.

51. Wilson, H.W., Amo-Addae, M., Kenu, E., et al. (2018) ‘Post-Ebola syndrome among Ebola virus disease survivors’, Lancet Infectious Diseases.

52. World Health Organization (2021) ‘A clinical case definition of post COVID-19 condition by a Delphi consensus’.